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Effectiveness and side effects of hormonal contraceptives
Shortly after the introduction of the contraceptive pill in 1960, the first case of venous thrombosis 
during use of an oral contraceptive was reported (1;2). The incidence of venous thrombosis in the 
general population is low, approximately 3 per 10 000 women-years among women in reproduc-
tive age. Despite the low incidence, use of oral contraceptives frequently causes venous throm-
bosis since millions of women worldwide use an oral contraceptive (3;4). Overall, combined oral 
contraceptive use is associated with a two- to six-fold increased risk of venous thrombosis (5-7). 
The aim of this thesis is to study the risk of venous thrombosis during use of different hormonal 
contraceptives, focusing on the pathogenesis, the evaluation of a marker to estimate the risk of 
venous thrombosis, and the assessment of effectiveness, side effects including the risk of venous 
thrombosis and acceptability of a new hormonal contraceptive.
Hormonal contraceptives and venous thrombosis
After the introduction of the first oral contraceptive pill, new prescriptions were developed 
to lower side effects like venous thrombosis, while maintaining the benefits of contraception 
and cycle control. The attempts that have been made to achieve this can be classified in four 
categories: 
1.  Lowering the hormone dose, 
2.  New formulas and schedules, 
3.  New steroids and 
4.  New routes of administration. 
Lowering the hormone dose
Because the estrogen compound in combined oral contraceptives was thought to cause the 
increased risk of venous thrombosis, the estrogen dose was stepwise reduced from 150 µg to 80 µg, 
50 µg, 30 µg, to 20 µg currently (8-11). Lowering this dose reduced the risk of venous thrombosis 
(5;8;9;12). The currently most prescribed combined oral contraceptives contain 20-30 µg estro-
gen in the form of ethinylestradiol.
New formulas and schedules of administration
Furthermore, new formulas and schedules of administration were introduced. The first oral con-
traceptives contained a fixed dose of estrogen and progestogen in a 21-day schedule, the mono-
phasic contraceptives. The multiphasic approach (biphasic and triphasic) was developed to mimic 
the natural cycle and improve acceptability (13). In these schedules, estrogens and progesto-
gens are administered in varying dosages in two or three phases during the cycle. The manufac-
turer claimed that the multiphasic approach imitates the natural menstrual cycle resulting in a 
better bleeding profile (14). However, the biphasic and triphasic preparations were evaluated and 
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compared with monophasic contraceptives in three systematic reviews which showed that the 
multiphasic approach had no advantages over the monophasic approach in contraceptive effec-
tiveness, side effects and cycle control and continuation rates (15-17). The thrombotic safety 
of multiphasic oral contraceptives compared with monophasic oral contraceptives was studied 
by Lidegaard et al. They compared monophasic with biphasic oral contraceptives containing 
levonorgestrel and ethinylestradiol and found no significant differences in thrombotic safety 
(adjusted rate ratio 1.07, 95% CI 0.75 to 1.52) (18).
New steroids
Another attempt to lower side effects of oral contraceptives was adjusting the chemical structure 
of progestogens. Progestogens were originally classified as first, second or third generation pro-
gestogens, based on the order of introduction and depending on their chemical structure. First 
generation progestogens (norethynodrel, norethisterone and lynestrenol) were developed in the 
1960s and are derived from the estrane steroids. Second generation (norgestrel and levonorg-
estrel) and third generation (desogestrel and gestodene) progestogens were developed in the 
1970s and 1980s and are derived from gonane steroids. Dienogest and drospirenone have been 
synthesized in the last 20 years and may be considered as fourth generation progestogens in a 
temporal fashion, although they do not share a common chemical structure (19). Drospirenone 
is derived from 17α-spironolactone, and was marketed internationally in 2000 (20). Dienogest is 
derived from the estrane steroids and was firstly marketed in 1995 in Germany, but only available 
in the Netherlands since 2008 (20). Cyproterone acetate is not included in the classification by 
generations. It was developed in the late 1980s and is derived from pregnane steroids. Since the 
characteristics of progestogens differ even within the generation groups, and the risk of venous 
thrombosis is dependent on the type of the progestogen instead of the generation, it is probably 
best to abstain from any classification of progestogens (21).
In 1995, three studies reported a two-fold increased risk of venous thrombosis in women using 
combined oral contraceptives containing the third generation progestogens gestodene and 
desogestrel compared with women using second generation oral contraceptives (5;7;22-26). 
Subsequently, cyproterone acetate containing oral contraceptives were also reported to have a 
two-fold increased risk compared with second generation combined oral contraceptives (23). In 
2009, the combined oral contraceptive containing drospirenone was found to increase the risk of 
venous thrombosis 1.7-fold compared with second generation oral contraceptives (23). Both oral 
contraceptives showed altered concentrations of coagulation factors and increased APC resis-
tance before the increased risk of venous thrombosis was identified in clinical trials. The ORs of 
different combined oral contraceptives known from recent literature are summarized in table 1.
Recently, a new combined oral contraceptive was marketed with a new estrogen: estradiol valerate 
(Qlaira ®, 2009, Bayer Schering Pharma, Berlin, Germany), which is an ester of the natural female 
hormone 17ß-estradiol. The progestogen compound is dienogest, a fourth generation progesto-
gen. The oral contraceptive is administered in a four-phasic (quadriphasic) schedule (20;27), with 
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an estrogen step-down and a progestogen step-up scheme and contains 26 acting tablets and 
two placebos on days 27 and 28 of the cycle. The manufacturer claimed that estradiol valerate 
and the quadriphasic scheme is more physiological, mimics the natural cycle and should there-
fore lead to fewer side effects and better acceptability (28). In chapter 2 the results of a Cochrane 
systematic review are presented in which the quadriphasic schedule of the combined oral contra-
ceptive containing dienogest and estradiol valerate was compared with monophasic oral contra-
ceptives, in terms of effectiveness, bleeding pattern, side effects and acceptability. 
New routes of administration
A third attempt to lower side effects was to develop new routes of administration of hormones, 
such as the vaginal ring and the transdermal patch. The rationale behind non-oral administration 
was a continuous release of hormones which bypass the first-pass liver effect. This should allow a 
lower estrogen and progestogen dose, less loss of bioavailability and fewer peaks in serum levels 
resulting in increased acceptability (29-34). 
The levonorgestrel-containing intra-uterine device (LNG-IUD, Mirena®, Bayer Schering Pharma, 
Berlin, Germany) is also a non-oral hormonal contraceptive, and available since 1990. It is inserted 
in the uterine cavity for a maximum of five years. It contains 52 mg levonorgestrel which is released 
continuously; the daily dose released in vivo is 14-20 µg per day and the circulating levonorg-
estrel plasma levels are 150-200 pg/mL. Use of levonorgestrel-only contraceptive pills results in 
higher levonorgestrel plasma levels of 800 pg/mL (35-37). The LNG-IUD showed no increased risk 
of venous thrombosis; reported odds ratios (ORs) vary from 0.3 to 0.57 (Table 1) (38;39). 
The transdermal patch (Ortho-Evra ®/Evra®, Ortho-McNeil-Janssen Pharmaceuticals, Raritan, NJ, 
USA) was marketed in 2002. It is a thin adhesive square of 20 cm2 which is applied on the skin 
(29;40) and continuously releases a daily dose of 203 µg norelgestromin (the active metabolite 
of norgestimate, a third generation progestogen (41)) and 33.9 µg ethinylestradiol for one week. 
According to the prescription, the patch is used in three consecutive weeks, followed by a patch-
free interval of one week in which a withdrawal bleeding may occur (40). 
The vaginal ring (NuvaRing®, Organon, Oss, The Netherlands) was marketed in 2001 and contains 
etonogestrel (a third generation progestogen) and ethinylestradiol. It is a flexible, soft, 4 mm 
thick ring of 5.4 cm in diameter which can easily be inserted into and removed from the vagina 
by the woman herself (31;42). The ring contains 11.7 mg etonogestrel and 2.7 mg ethinylestradiol 
and continuously releases a daily dose of 120 µg etonogestrel and 15 µg ethinylestradiol over a 
period of 3 weeks (42). 
Despite attempts to reduce side effects such as venous thrombosis, the transdermal patch and 
vaginal ring did not lead to a lower thrombotic risk than with use of oral contraceptives contain-
ing levonorgestrel: the Food and Drug Administration (FDA) reported an OR of 7.9 (95% CI 3.5 
to 17.7) during use of the transdermal patch and an OR of 6.5 (95% CI 4.7 to 8.9) during use of 
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the vaginal ring (Table 1) (43) compared with four low-estrogen combined hormonal contracep-
tives. These increased risks were later confirmed by Lidegaard et al. , in a large Danish cohort (39). 
The high thrombotic risk of the vaginal ring may be caused by its release of a third generation 
progestogen which is associated with an increased thrombotic risk, as described above. During 
use of the transdermal patch, 60% higher estrogen levels were measured than with a combined 
oral contraceptive containing the same steroids, which is associated with a higher risk of venous 
thrombosis (40;44).
Table 1: Odds ratios and 95% confidence intervals of hormonal contraceptives. All oral contraceptives  
All for preparations that contain 30-37.5 µg ethinylestradiol.
Contraceptive OR 95% CI Reference
Non use (reference) 1.0 - -
Combined oral contraceptive Lynestrenol 5.6 3.0 – 10.2 (23)
Norethisterone 3.9 1.4 – 10.6 (23)
Levonorgestrel 3.2 2.5 – 3.9 (21)
Desogestrel 5.5 4.4 – 6.8 (21)
Gestodene 4.6 3.6 – 5.9 (21)
Norgestimate 3.9 2.9 – 5.4 (21)
Cyproterone Acetate 5.5 3.9 – 7.7 (21)
Drospirenone 6.0 4.1 – 8.9 (21)
Transdermal Patch Norelgestromin 7.9 3.5 – 17.7 (43)
Vaginal ring Etonogestrel 6.5 4.7 – 8.9 (43)
Levonorgestel - IUD Levonorgestrel 0.6 0.4 – 0.8 (38;39)
Biological explanation
The exact biological mechanism of the increased risk of venous thrombosis during oral contraceptive 
use and the differences between the different oral contraceptives is unknown. Various studies showed 
altered levels of clotting factors during use of combined oral contraceptives. Increased levels of the 
procoagulant factors prothrombin, factor VII, VIII, IX, X, XI, XII, von Willebrand factor and fibrinogen, and 
decreased levels of the anticoagulant factors protein S and antithrombin were observed (45-48). The 
interpretation of the changes in clotting factors differed between researchers, since the net effect of 
changes of the haemostatic system was not known.
APC resistance
A major step forward in the biological understanding of the increased risk of venous thrombosis 
during use of oral contraceptives was the observation that oral contraceptives induce an acquired 
form of resistance to Activated Protein C (APC) (49;50). APC is a physiological anticoagulant 
which inactivates factor V and thereby inhibits coagulation. APC resistance is the relative inability 
of activated protein C to cleave activated factor V or factor VIII, leading to a prothrombotic state. 
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It was first described by Dählback et al. in a family with a hereditary tendency for venous throm-
bosis (51). A year later, Bertina et al. identified the factor V Leiden mutation (replacement of the 
amino acid Arg506 by Gln), which is the most common form of hereditary APC resistance (52). APC 
resistance not caused by the factor V Leiden mutation is also an important risk factor for venous 
thrombosis (53;54).
APC resistance was originally measured by the aPTT-based APC resistance test, which measures 
the effect of APC on the clotting time of plasma in which coagulation is initiated via the intrin-
sic pathway (55). In 1995 the thrombin generation-based APC resistance test was developed by 
Rosing and Hemker (56;57). The test quantifies the effect of APC on the time integral of thrombin 
formation in plasma in which coagulation is initiated via the extrinsic coagulation pathway. The 
test is a global assay, which includes the effects on individual clotting factors (procoagulant 
and anticoagulant factors) and combines them into a net effect (56;57). Women using combined 
oral contraceptives were found to be resistant to APC by this thrombin generation-based APC 
resistant test. More importantly, differences in APC resistance between users of second and third 
generation combined oral contraceptives were shown, and the test provided an explanation for 
the differences in venous thrombosis risk between the oral contraceptives (58;59). The thrombin 
generation-based APC resistance test was validated in the Leiden Thrombophilia Study and pre-
dicts the risk of venous thrombosis in users of combined oral contraceptives as well as in non-
users and men (60). 
TFPI and Protein S
The two main determinants of the thrombin generation-based APC resistance test are free Protein 
S and free Tissue Factor Pathway Inhibitor (TFPI) (61-63). Hereditary and acquired deficiencies of 
Protein S and low plasma levels of TFPI are associated with an increased risk of venous throm-
bosis (64-67). Moreover, Protein S-deficient individuals also have decreased TFPI levels, probably 
due to common mechanisms regulating biosynthesis of both proteins (64). Van Vliet et al. observed 
that women using combined oral contraceptives with the highest risk of venous thrombosis (i.e. 
containing desogestrel, cyproterone acetate or drospirenone) had lower free Protein S and free 
TFPI levels compared with women using the combined oral contraceptive with the lowest risk of 
venous thrombosis (i.e. containing levonorgestrel). The study concluded that the differences in 
APC resistance, induced by combined oral contraceptives, can at least partially be explained by 
differences in free Protein S and free TFPI (61). 
Chapter 3 describes a study which evaluates whether the different risks of venous thrombosis 
caused by different hormonal and non-hormonal methods of contraception are reflected in the 
levels of free TFPI and free Protein S. The association of these levels with APC resistance mea-
sured by the thrombin generation-based APC resistance test, and with relative risks as reported 
in the literature is examined.
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Predicting thrombotic risk by use of markers
When a new hormonal contraceptive is introduced, an estimation of the thrombotic risk is required 
in order not to expose women to an unnecessary high risk of venous thrombosis by prescribing 
this new contraceptive. As the result of the high number of participants required for a clinical 
study due to the low incidence of venous thrombosis, assessment of the thrombotic risk of new 
contraceptives in clinical preregistration studies is unfeasible. In order to demonstrate a doubling 
of the risk of venous thrombosis between two different combined hormonal contraceptives with 
a power of 80% and a significance level of 5%, a cohort of approximately 500 000 women would 
need to be followed for 1 year (68). 
To predict the risk of venous thrombosis of a new hormonal contraceptive before market authori-
zation, one can revert to a study with markers. A marker is a proxy, usually a laboratory test, for a 
clinical outcome. They make it possible to perform a study with smaller sample sizes and shorter 
observation periods than necessary for true clinical outcomes. Preferably, a marker is validated in 
a study in which both the marker and the clinical endpoint are assessed (69). An important, and 
validated marker for venous thrombosis during use of hormonal contraceptives is APC resistance, 
measured by the thrombin generation-based APC resistance test (expressed in normalized APC 
sensitivity ratios, nAPCsr), since it differentiates well between “low-risk” and “high-risk” oral con-
traceptives (60).
In search of other markers, Odlind et al. suggested Sex Hormone-Binding Globulin (SHBG) as 
marker of “estrogenicity” and thereby venous thrombosis (70). SHBG is a carrier protein produced 
in the liver and transports testosterone and estrogen. The effect of an oral contraceptive on SHBG 
levels can be interpreted as the sum of the dose-related estrogenic effect of ethinylestradiol 
and the dose- and type-related anti-estrogenic effect of the progestogen, resulting in the total 
“estrogenicity” of the oral contraceptive (70). In two observational studies, an association between 
APC resistance and SHBG levels was found in users of different hormonal contraceptives and non-
users which support the “estrogenicity” hypothesis (71;72). 
To determine whether SHBG is a useful marker for the risk of venous thrombosis of combined 
oral contraceptives, we conducted an observational study assessing SHBG levels in non-users, 
users of the hormonal and non-hormonal IUD, and users of different oral contraceptives. The 
results of the comparison between the SHBG levels, nAPCsr, and the risks of venous thrombosis 
as reported in the literature are described in chapter 4. Besides, we investigated whether an 
ethinylestradiol-dose related increase in SHBG levels is present during use of different combined 
oral contraceptives, which is described in chapter 5. 
The absolute and relative risk of venous thrombosis during use of the above mentioned recently 
introduced combined oral contraceptive is unknown. Chapter 6 describes a randomized controlled 
trial in which APC resistance and SHBG levels during use of the combined oral contraceptives 
containing dienogest/estradiol valerate and levonorgestrel/ethinylestradiol were compared. 
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Thyroid parameters and venous thrombosis
There are many risk factors for venous thrombosis, which can be broadly defined in those related 
to immobilization and to changes in coagulability. The latter can be divided in genetic abnormali-
ties in the coagulation system, and acquired factors, amongst which are cancer and use of oral 
contraceptives. Besides the use of hormonal contraceptives, hyperthyroidism is also associated 
with an increased risk of venous thrombosis (73-77) and causes a hypercoagulable state with 
increased levels of procoagulant and anticoagulant factors. Hyperthyroidism increases antifibrino- 
lysis and induces changes in the inflammatory pathway through complement C3 which induces a 
hypercoagulable state (45;77). The hypercoagulable state is probably due to high free Thyroxine 
(T4) levels which influence the coagulation system (73-75). 
During use of hormonal contraceptives, Thyroxine-Binding Globulin (TBG) levels are increased 
(70;78-83). TBG is a hepatic globulin which transports thyroid hormones. Higher TBG levels lead 
to higher total T4 and total Tri-iodothyronine (T3) levels. Like SHBG, TBG levels are associated 
with the increased risk of venous thrombosis during use of hormonal contraceptives (70;71). 
Whether the increased levels of thyroid parameters during use of hormonal contraceptives are 
associated with the increased risk of venous thrombosis during use of these contraceptives has 
not yet been studied. 
In chapter 7 we questioned whether there is an association between the levels of TBG, FT4 
and TSH during use of hormonal contraceptives and the risk of venous thrombosis. The study 
examines whether an association can be found between thyroid parameters and APC resistance 
measured with the thrombin generation-based APC resistance test and the thrombotic risks as 
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Quadriphasic oral contraceptives have been developed to reduce the adverse effects of oral con-
traceptives and are presented as more physiological since theymimic the natural cycle. However, 
suggested disadvantages of quadriphasic oral contraceptives include a possible increased risk of 
pill-taking errors caused by the array of different color pills, complicated directions for catching 
up when a pill is missed, the higher price and potential inferiority in terms of side effects.
Objectives
To compare the contraceptive effectiveness, bleeding pattern, minor side effects and acceptability 
of quadriphasic contraceptive pills versus monophasic contraceptive pills.
Search methods
We searched CENTRAL, MEDLINE, EMBASE, POPLINE, ClinicalTrials.gov and ICTRP for trials com-
paring quadriphasic pills with monophasic pills. We contacted researchers and manufacturers of 
quadriphasic oral contraceptives to identify additional studies.
Selection criteria
Randomized controlled trials (RCTs) comparing quadriphasic with monophasic oral contracep-
tives. Trials had to report on contraceptive effectiveness, bleeding patterns, minor side effects, 
ease of use or trial discontinuation. We excluded studies where the intervention was primarily 
used as a treatment for disorders or was administered for fewer than three consecutive cycles.
Data collection and analysis
Two authors abstracted and entered data into RevMan. We critically appraised the methodologi-
cal quality of the included trials. For continuous variables, we computed the mean difference 
with 95% confidence interval (CI) using the random-effects model. For dichotomous variables, we 
calculated the risk ratio with 95% CI using the random-effects model.
Main results
We included one double-blind, double-dummy RCT comparing a quadriphasic oral contraceptive 
composed of dienogest and estradiol valerate with a monophasic oral contraceptive composed of 
levonorgestrel and ethinylestradiol. Contraceptive effectiveness, intracyclic bleeding and discon-
tinuation due to side effectswere similar for quadriphasic andmonophasic pills. The number of 
women experiencing withdrawal bleeding was higher in the monophasic group compared to the 
quadriphasic group.Users of quadriphasic pills reported fewer bleeding/spotting days and fewer 
bleeding/spotting episodes than users of monophasic pills but the report did not specify whether 
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the bleeding/spotting was scheduled or unscheduled. More women using quadriphasic oral con-
traceptives reported breast pain compared to women using monophasic oral contraceptives.
Authors’ conclusions
The available evidence is insufficient to determine whether quadriphasic differ from monophasic 
oral contraceptives in contraceptive effectiveness, bleeding pattern, minor side effects and accept-
ability. Studies that compare quadriphasic and monophasic oral contraceptives with an identical 
progestogen and estrogen type are needed to determine whether the quadriphasic approach 
differs from the monophasic approach. Studies that compare quadriphasic pills with monophasic 
pills containing 30 µg ethinylestradiol are indicated to determine whether quadriphasic oral 
contraceptives have an advantage over the current, first choice oral contraceptive. Until then, we 





Birth control pills with three phases versus one phase
Standard birth control pills contain two hormones: progestogen and estrogen. One-phase birth 
control pills contain the same dose of progestogen and estrogen every day. Four-phase birth 
control pills contain different amounts of progestogen and estrogen on different days. This 
review looked at how well one-phase birth control pills and four-phase birth control pills work 
to prevent pregnancy, how often they cause bleeding problems, how often users experience side 
effects and how many women stop using the pills. 
We did a computer search for randomized controlled trials comparing four-phase birth control 
pills with one-phase birth control pills. We also wrote to researchers and makers of birth control 
pills to find other trials. Studies had to report on pregnancy, bleeding problems, side effects or 
stopping the use of pills. We did not include studies where the pills were used as a treatment for 
disorders like acne, hirsutism, polycystic ovary syndrome, bleeding problems or endometrioses, or 
where the pills were administered for less than three months. We assessed whether the studies 
were conducted properly.
We included one study comparing a four-phase pill composed of the progestogen dienogest and 
the estrogen estradiol valerate with an one-phase pill composed of the progestogen levonorg-
estrel and the estrogen ethinylestradiol. Four-phase birth control pills and onephase birth control 
pills had similar pregnancy rates. The number of women with blood loss in the period between 
two menstruations was similar for four-phase pills and one-phase pills. More women using one-
phase birth control pills had a menstruation compared to women using four-phase birth control 
pills. The number of women who stopped using the pills because of side effects was similar for 
four-phase pills and one-phase pills. Breast pain was reported more frequently by women who 
used four-phase birth control pills than women who used one-phase birth control pills.
The presence of only one study made it impossible to adequately compare four-phase birth 
control pills with one-phase birth control pills. More studies are needed to determine whether 
four-phase pills have advantages over one-phase pills. Until then, we recommend one-phase pills 
containing 30 µg estrogen for women starting to use birth control pills.
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Background
Since the introduction of combined oral contraceptives in the 1960s, the development of new 
hormonal contraceptives has focused on reducing the adverse effects while maintaining the 
benefits. Four approaches have been used to reduce the adverse effects of oral contraceptives 
and so increase compliance: (I) lowering of the steroid dose, (II) development of new steroids, 
(III) development of new formulas and schedules of administration, and (IV) development of new 
routes of administration.
Initially oral contraceptives contained a fixed dose of estrogen and progesterone for 21 days: so-
called monophasic preparations. In order to provide better cycle control, biphasic and triphasic 
oral contraceptives were developed in the 1970s and 1980s (1). These preparations consist of two 
or three phases, each with a different progesterone dosage and in some preparations estrogen 
dosage. In the first phase progestogen levels are low, followed by a higher dose of the steroids in 
the second and third phases. To date, no benefits of the bi- and triphasic approach compared to 
the monophasic approach have been demonstrated (2;3).
Recently, the first quadriphasic oral contraceptive has been introduced. The rationale behind the 
development of the quadriphasic approach was to improve the unsatisfactory bleeding patterns 
observed with 17ß-estradiol-containing, mono- and biphasic oral contraceptives (4-6). Further, the 
quadriphasic approach is presented as more physiological since it mimics the natural cycle (7;8). 
Limited data are available on the contraceptive effectiveness, bleeding pattern and adverse effects 
of quadriphasic oral contraceptives.
Description of the intervention
Combined oral contraceptives consist of a progestogen component and an estrogen component.
Monophasic preparations contain the same dose of progestogen and estrogen every day. In mul-
tiphasic oral contraceptives, the progestogen dosage, and in some preparations the estrogen 
dosage, varies over the cycle. Currently there is one quadriphasic preparation on the market. This 
oral contraceptive contains estradiol valerate 3 mg on days 1 and 2; dienogest 2 mg and estra-
diol valerate 2 mg on days 3 to 7; dienogest 3 mg and estradiol valerate 2 mg on days 8 to 24; 
estradiol valerate 1 mg on days 25 and 26; and placebo on days 27 and 28.
How the intervention might work
Combined oral contraceptives prevent ovulation by inhibiting gonadotropin secretion (1). 
Ovulation is primarily suppressed by the progestogen component, which prevents the LH-surge 
by inhibiting luteinizing hormone (LH) secretion. The estrogen component suppresses folli-
cle-stimulating hormone (FSH) secretion but its major role is stabilizing the endometrium to 
minimize spotting and breakthrough bleeding. Other contraceptive effects of the progestogen com-
ponent include thickening of the cervical mucus and altering the endometrium in a decidualized 
bed with atrophied glands.
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Why it is important to do this review
Limited data are available on the contraceptive effectiveness, bleeding pattern and adverse 
effects of quadriphasic oral contraceptives. Suggested benefits of the quadriphasic oral contra-
ceptive containing dienogest and 17ß-estradiol include better bleeding patterns and favorable 
effects on metabolic and hemostatic variables (4;9-11). However, disadvantages of quadriphasic 
oral contraceptives include a possible increased risk of pill-taking errors caused by the array of 
different color pills, complicated directions for catching up when a pill is missed, the higher price 
and potential inferiority in terms of side effects (7).
We systematically reviewed the literature to summarize the available evidence on the benefits 
and disadvantages of the quadriphasic approach. The results of the systematic review can assist 
healthcare providers in counseling women making contraceptive choices. A summary of the 
available evidence may also be useful for researchers in planning future studies.
Objectives
The aim of this review was to compare the contraceptive effectiveness, bleeding pattern, minor 
side effects and acceptability of quadriphasic oral contraceptive pills versus monophasic oral 
contraceptive pills.
Methods
Criteria for considering studies for this review
Types of studies
We included randomized controlled trials in any language. We excluded non-randomized trials.
Types of participants
We included all women of reproductive age enrolled in the randomized controlled trials. 
Eligibility criteria were those used by the researchers. We included women starting oral contra-
ceptives as well as women switching oral contraceptives.
Types of interventions
Interventions included any quadriphasic oral contraceptive pill compared to any monophasic oral 
contraceptive pill when used to prevent pregnancy. We excluded studies where the intervention 
was primarily used as a treatment for disorders, e.g. acne, hirsutism, polycystic ovary syndrome, 
dysmenorrhea, menorrhagia or endometriosis. Interventions had to be applied for a minimum of 
three consecutive cycles to be eligible for inclusion.
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Types of outcome measures
primary outcomes
The main outcome was pregnancy. We did not include studies which focus on follicular growth 
or ovulation.
secondary outcomes
Other outcomes were bleeding patterns, minor side effects, ease of use and trial discontinuation. 
We excluded studies which primarily focus onmetabolic and hemostatic outcome measures. The 
definitions of bleeding indices were those specified by the authors.
Search methods for identification of studies
Electronic searches
We searched the Cochrane Central Register of Controlled Trials (CENTRAL),MEDLINE, EMBASE and 
POPLINE for publications comparing quadriphasic withmonophasic oral contraceptive pills. In 
addition, we searched for current trials through Clinical- Trials.gov and the International Clinical 
Trials Registry Platform (ICTRP). The search strategies are shown below.
MEDLINE
contraceptives, oral [mesh] AND (quadrophasic OR four phasic OR four-phasic OR quadri-step 
OR quadro-step OR quadro step OR “four phasic” OR four-phase OR “four phase” OR “dynamic 
dosing”)
Limited to: humans, female, clinical trial, meta-analysis, randomized controlled trial, review, 
comparative study, controlled clinical trial, multicenter study
POPLINE
(oral contraceptive*/oral contraceptive agent*) & (quadriphasic/quadrophasic/four phasic/four-
phasic/“quadri step”/quadri-step/“quadro step”/ quadro-step)
EMBASE
(oral contraceptive or oral contraceptive agent) and (quadriphasic or quadrophasic or four phasic 
or four-phasic or “quadri step” or quadri-step or “quadro step” or quadro-step)
CENTRAL
oral contraceptives and phasic
ClinicalTrials.gov




oral contraceptives and quadriphasic
Searching other resources
We reviewed the reference lists of identified studies, review articles and book chapters for addi-
tional trials. We contacted the authors of the included trials and pharmaceutical companies mar-
keting quadriphasic oral contraceptives to inquire whether they were aware of any published or 
unpublished studies which we have missed with our search.
Data collection and analysis
Selection of studies
One author assessed for inclusion or exclusion all titles and abstracts identified during the litera-
ture searches under unblinded conditions.
Data extraction and management
One author extracted the data from the included studies under unblinded conditions and entered 
the data into RevMan (12). In addition to the methodological quality of the study and outcome 
measures, we extracted data on participants, inclusion and exclusion criteria, study sites, dura-
tion of study, study medication, method of collecting the data and funding source. Another author 
performed a second, independent data abstraction and verified the correct entry of the data. No 
disagreements about the extracted and entered data occurred.
Assessment of risk of bias in included studies
We critically appraised the methodological quality of the trials according to the recommended 
principles described in the Cochrane Handbook (13). We focused on the method of generating the 
allocation sequence, the use and method of allocation concealment, the use and method of blind-
ing, exclusion of participants after randomization, discontinuation and loss to follow-up. Limita-
tions in study design are presented in Risk of bias in included studies, Characteristics of included 
studies, Figure 1 and Figure 2, and are discussed in the Quality of the evidence section.
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Figure 1. Methodological quality graph: review authors’ judgements about each methodological quality 
item presented as percentages across all included studies.
Dealing with missing data
We contacted the authors of the eligible and possibly eligible trials for additional information 
about the study methods and the various outcome measures.
Assessment of heterogeneity
Since only one study was eligible for inclusion we could not assess heterogeneity by the Chi2 test 
or assess the impact on the meta analysis using the I2 statistic.
Data synthesis
We compared the contraceptive effectiveness, bleeding patterns, minor side effects and trial 
discontinuation between quadriphasic oral contraceptives and monophasic oral contraceptives. 
The included study reported the number of women who became pregnant, the mean number of 
bleeding/spotting days with standard deviation, the mean number of bleeding/spotting episodes 
with standard deviation, the number of women discontinuing early due to side effects and the 
number of women reporting a particular adverse effect. In addition, the authors provided us the 
number of women with intracyclic bleeding and the number of women with withdrawal bleeding 
per cycle. No data on ease of use were mentioned in the paper or provided by the authors. For 
continuous variables, we computed the mean difference with 95% confidence interval using the 
random-effects model. For dichotomous variables, we calculated the risk ratio with 95% confi-
dence interval using the random-effects model.
Subgroup analysis and investigation of heterogeneity
Since only one study was included we could not conduct a subgroup analysis by examining only 
studies with high methodological quality, i.e. studies with an adequate method of generating 
the allocation sequence, an adequate method of allocation concealment, an adequate method of 
Random sequence generation (selection bias)
Allocation concealment (selection bias)
Blinding (performance bias and detection bias)
Incomplete data (attrition bias)
Public funds
0% 25% 50% 75% 100%
Low risk of bias Unclear risk of bias High risk of bias
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blinding and less than 20% loss to follow-up. A subgroup analysis including only starters/switch-
ers was also not performed because the outcomes were not reported according to whether the 
woman was a starter or switcher.
Results
Description of studies
See: Characteristics of included studies.
Results of the search
The search strategy yielded 31 papers. Four studies were nonrandomized. Twenty-six studies did 
not meet our inclusion criteria or focused on outcomes not included in this review. 
Included studies
One study met the inclusion criteria for this review (A). The study compared a quadriphasic oral 
contraceptive composed of estradiol valerate 3 mg on days 1 and 2; dienogest 2 mg and estradiol 
valerate 2 mg on days 3 to 7; dienogest 3 mg and estradiol valerate 2 mg on days 8 to 24; estra-
diol valerate 1 mg on days 25 and 26; and placebo on days 27 and 28, with a monophasic oral 
contraceptive composed of levonorgestrel 100 µg and ethinylestradiol 20 µg on days 1 to 21 and 
placebo on days 22 to 28. The trial included 804 randomized women of whom 402 were allocated 
to the quadriphasic group and 402 to the monophasic group. The study lasted seven cycles and 
included 20 822 womenyears. The main objective of the study was to compare bleeding pattern 
and cycle control with the two preparations. Secondary outcome measures were the number of 
unintended pregnancies, satisfaction with the treatment and safety. Detailed information regard-
ing participants, inclusion and exclusion criteria, study sites, duration of study, study medication 
and outcome measures is presented in the Characteristics of included studies.
Excluded studies
There are no excluded studies.
Risk of bias in included studies
Allocation
Randomization was done by a computer-generated random allocation sequence generated at 
the sponsor’s central randomization service. The study did not report the use and method of con-
cealing the treatment allocation sequence. Communication with the authors revealed no extra 
information.
35
Quadriphasic versus monophasic oral contraceptives for contraception
Blinding
The study is described as a double-blind, double-dummy trial. The paper does not specify who 
was kept unaware of the oral contraceptives assigned and does not provide information regard-
ing successful implementation of blinding. Communication with the authors revealed no extra 
information.
Incomplete outcome data
The study reported detailed information on number and reasons for discontinuation. Of the 402 
women in the quadriphasic group, 37 women (9%) discontinued early, as did 40 women (10%) 
of the 402 women in the monophasic group. Three women in both groups did not receive the 
oral contraceptives after randomization. Fourteen women in the quadriphasic and 15 women in 
the monophasic group were withdrawn because of protocol violations. No women were lost to 
follow-up. Communication with the authors indicated analysis according to the intention-to-treat 
principle without further specification.
Other potential sources of bias
Funding
The trial was supported by the manufacturer of the studied quadriphasic and monophasic pills.
Effects of interventions
Contraceptive effectiveness
No significant difference in contraceptive effectiveness was observed between the quadriphasic 
and monophasic pills (Analysis 1.1). The study describes one unintended pregnancy caused by a 
method failure in the monophasic group.
Cycle control and bleeding pattern
Intracyclic bleeding
Additional data on intracyclic bleeding was provided by the authors. Overall, the number of 
women experiencing intracyclic bleeding did not differ between the quadriphasic and monopha-
sic preparation (Analysis 1.2 to Analysis 1.15). During the fourth cycle the proportion of women 
having intracyclic bleeding was higher in the quadriphasic group compared to the monophasic 
group (risk ratio (RR) 1.45; 95% confidence interval (CI) 1.01 to 2.10).
Withdrawal bleeding
Data on withdrawal bleeding not described in the paper were provided by the authors. During 
each treatment cycle the proportion of women with withdrawal bleeding was higher in the mono-
phasic group compared to the quadriphasic group (Analysis 1.16 to Analysis 1.22 and Figure 2; 
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at cycle 3 RR 0.88; 95% CI 0.83 to 0.93; at cycle 6 RR 0.89; 95%CI 0.84 to 0.94). Further, the 
paper describes that the duration and intensity of withdrawal bleeding was shorter and lighter 
in women using quadriphasic oral contraceptives compared to women using monophasic oral 
contraceptives.  The median length of withdrawal bleeding was 4.0 days for users of quadriphasic 
pills versus 5.0 days for users of monophasic pills (reported P < 0.05). Themedian intensity score 
of withdrawal bleeding was 3 (light) for women using quadriphasic oral contraceptives compared 
to 4 (normal) for women using monophasic oral contraceptives.
Spotting/bleeding
Women using quadriphasic oral contraceptives reported fewer bleeding/spotting days (Analysis 
1.23; Analysis 1.24; Figure 3; reference period one mean difference (MD) -4.20; 95%CI -5.52 to - 
2.88; reference period twoMD-2.50; 95%CI -3.65 to -1.35) and fewer bleeding/spotting episodes 
(Analysis 1.25; Analysis 1.26; Figure 4; reference period one MD -0.40; 95% CI -0.56 to - 0.24 refer-
ence period two MD -0.10; 95% CI -0.26 to 0.06) than women using monophasic oral contracep-
tives. The report did not specify whether the bleeding/spotting was scheduled or unscheduled.
Discontinuation
The number of women who discontinued due to adverse effects did not differ between quadri-
phasic and monophasic oral contraceptives (Analysis 1.27). No discontinuations because of bleed-
ing disorders occurred.
Side effects
During the study period significantly more women using quadriphasic oral contraceptives reported 
breast pain compared to women using monophasic oral contraceptives (Analysis 1.30; Figure 5; 
RR 3.25; 95% CI 1.07 to 9.88). The number of women reporting headache, acne, alopecia, migraine 
and increase in body weight did not differ between the two preparations (Analysis 1.28; Analysis 
1.29; Analysis 1.31 to Analysis 1.35).
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Discussion
Summary of main results
We identified only one trial including 804 women which compared a quadriphasic oral contracep-
tive composed of estradiol valerate 3 mg on days 1 and 2; dienogest 2 mg and estradiol valerate 
2 mg on days 3 to 7; dienogest 3 mg and estradiol valerate 2 mg on days 8 to 24; estradiol valer-
ate 1mg on days 25 and 26; and placebo on days 27 and 28, with a monophasic oral contraceptive 
composed of levonorgestrel 100 µg and ethinylestradiol 20 µg on days 1 to 21 and placebo on 
days 22 to 28 (A). 
The outcomes were contraceptive effectiveness, bleeding pattern, side effects and discontinua-
tion due to side effects. Users of quadriphasic oral contraceptives were less likely to experience 
a withdrawal bleeding compared to users of monophasic oral contraceptives. Additionally, the 
duration and intensity of the withdrawal bleeding was lower in the group of women using quad-
riphasic oral contraceptives. In the group of quadriphasic pill users more women reported breast 
pain compared to the group of monophasic pill users. The contraceptive effectiveness, intracyclic 
bleeding and discontinuation due to side effects did not differ between the two groups.
Overall completeness and applicability of evidence
The presence of only one study including 804 women for seven treatment cycles made it impos-
sible to adequately compare the quadriphasic approach with the monophasic approach in terms 
of contraceptive effectiveness, bleeding pattern, side effects and discontinuation due to side 
effects. The two studied preparations differed in progestogen and estrogen content. Since the 
progestogen as well as the estrogen type is thought to affect cycle control, the observed differ-
ences in bleeding pattern might be (partially) explained by the differences in progestogen and 
estrogen type rather than the phasic approach. In addition, the quadriphasic oral contraceptive 
was compared with a monophasic oral contraceptive containing 20 µg ethinylestradiol. Contra-
ceptive pills containing 20 µg ethinylestradiol have been shown to result inmore bleeding dis-
turbances and discontinuation due to side effects than contraceptive pills containing more than 
20 µg ethinylestradiol (14).
Quality of the evidence
The study featured an adequate method of generating a random allocation sequence, was 
reported to be double-blinded and had low discontinuation rates. Limitations of the methodologi-
cal quality of the trial included no description of the use or method of allocation concealment, no 
specification of who was kept unaware of the assigned treatment, exclusion of participants after 
randomization and funding of the trial by the manufacturer of the quadriphasic pill. Inadequate 
methods of allocation concealment and exclusion of participants after randomization may lead 
to bias (15;16). Studies sponsored by pharmaceutical companies are more likely to have outcomes 
favoring the sponsor than studies funded by other sources (17;18).
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Potential biases in the review process
No potential biases in the review process were evident.
Agreements and disagreements with other studies or reviews
Beside the included randomized controlled trial, two multicentre, non-comparative trials assess-
ing the contraceptive effectiveness, bleeding pattern, minor side effects, early discontinuation 
and satisfaction during use of the quadriphasic dienogest/estradiol valerate oral contraceptive 
have been conducted (19;20). Both studies were funded by the manufacturer of the quadriphasic 
pill. One study has been published in a peer-reviewed journal (20). In this study 13 pregnancies 
occurred during 23,368 cycles of quadriphasic dienogest/estradiol valerate use (Pearl Index 0.73). 
No data on bleeding pattern were reported. The paper describes that 272 of the 1377 users of 
the dienogest/estradiol valerate oral contraceptive (19.8%) reported adverse effects related to 
the treatment; breast pain was most commonly mentioned (50 users; 3.6%). During the study 140 
participants (10.2%) discontinued early due to adverse effects. All reviews, which are narrative, 
rely on the included randomized trial and the two non-comparative trials (4-6).
Author’s conclusions
Implications for practice
We recommend monophasic oral contraceptives as the first choice for women starting oral con-
traceptive use, given the absence of proven advantages of the quadriphasic approach, the greater 
complexity of quadriphasic pill regimens, the higher costs of quadriphasic oral contraceptives and 
the sparse experience with quadriphasic pills. At first prescription, monophasic pills containing 
30 µg estrogen are preferred over monophasic pills containing 20 µg since the latter cause more 
bleeding disturbances and discontinuation (14). Women experiencing heavy menstrual bleeding 
may benefit from quadriphasic oral contraceptives but continuous use of a monophasic oral con-
traceptive to avoid menstrual bleeding may also be an alternative.
Implications for research
All new contraceptive preparations require comparison of contraceptive effectiveness, bleeding 
pattern, side effects, discontinuation rates and beneficial effects with a gold standard in 
large, adequately reported, high-quality, randomized controlled trials. Studies that compare quadri- 
phasic and monophasic oral contraceptives with an identical progestogen and estrogen type are 
needed to determine whether the quadriphasic approach differs from the monophasic approach. 
Trials that compare quadriphasic pills with monophasic pills containing 30 µg ethinylestradiol 
are indicated to determine whether quadriphasic oral contraceptives have an advantage over 
currently and widely used oral contraceptives with which providers and consumers have 
extensive experience.
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Characteristics of studies
Characteristics of included studies [ordered by study ID]
Ahrendt 2009
Methods Double-blind randomized controlled trial
Participants 846 women at 34 sites in Europe
Inclusion criteria were healthy women aged 18 to 50 years
Exclusion criteria were pregnancy; lactation; fewer than 3 menstrual 
cycles following childbirth, abortion or lactation; current use of an IUD; 
BMI more than 30 kg/m2; use of long-acting progestins within 6 months 
prior to the study entry; hypersensitivity to study drug ingredients; known 
or suspected malignant or pre-malignant disease; more than 10 cigarettes 
per day when aged 18 to 30 years or smoking when aged older than 30 
years; use of other sex steroids
Starters and switchers were included in the study
Interventions Quadriphasic dienogest/estradiol valerate (E2V 3 mg on days 1 and 2,  
DNG 2 mg and E2V 2 mg on days 3 to 7, DNG 3 mg and E2V 2 mg on days 
8 to 24, E2V 1 mg on days 25 and 26 and placebo on days 27 and 28) ver-
sus monophasic levonorgestrel/ethinylestradiol (LNG 100 µg and 20 µg  
EE on days 1 to 21 and placebo on days 22 to 28). Women were instructed 
to take the tablets at the same time each day and to take any missed tab-
lets as soon as remembered. If the interval between taking two consecu-
tive tablets was more than 36 hours a non-hormonal contraceptive had  
to be used
Outcomes The primary outcome measures are cycle control and bleeding patterns
Secondary outcomemeasures include the number of unintended pregnan-
cies, satisfaction with treatment and safety
Scheduled bleeding was defined as a bleeding or spotting episode that 
began during the hormone-free period or started not more than 4 days 
before the progestin withdrawal in any cycle that continued through into 
the progestin-free interval. Absence of scheduled bleeding was defined 
as no bleeding until day 20 of consecutive cycles with the quadriphasic 
preparation and day 17 with the monophasic preparation
Unscheduled bleeding was defined as all other bleeding episodes
A bleeding/spotting episode was defined bleeding/spotting days bounded 
on either end by equal or more than 2 days of no bleeding/spotting
Use of daily diary cards to collect data on pill intake and cycle control. 
Data on side effects were recorded if reported spontaneously
Notes The report does not provide an a priori hypothesis. The report states a 
sample size which was chosen to obtain an acceptable estimate of the 
number of women required to permit acceptably precise comparisons 
between groups for the number of bleeding/spotting days per reference 




Bias Authors’ judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Randomization by a computer-generated random 
allocation sequence
Allocation concealment  
(selection bias)
Unclear risk The use of allocation concealment is not de-
scribed. Communication with the authors revealed 
no extra information
Blinding (performance bias 
and detection bias)
All outcomes
Low risk The study is reported as a double-blind, double-
dummy trial. Who was kept unaware of the oral 
contraceptives assigned is not described. Com-
munication with the authors revealed no extra 
information
Incomplete outcome data  
(attrition bias)  
All outcomes
Low risk 37 women in the quadriphasic group and 40 wom-
en in the monophasic group discontinued early. 
The reasons for discontinuation are described. 
3 women in each group did not receive the oral 
contraceptives. No women were lost to follow-up. 
14 women in the quadriphasic and 15 women in 
the monophasic group were withdrawn because of 
protocol violations. Unclear whether the analysis 
was according to the intention-to-treat principle. 
Communication with the authors indicated an 
analysis according to intention-to-treat without 
further specification
Public funds High risk The trial was supported by the manufacturer of the 
studied quadriphasic and monophasic pills
BMI: body mass index; DNG: dienogest; E2V: estradiol valerate; EE: ethinylestradiol; IUD: intrauterine 
device; LNG: levonorgestrel
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Data and analyses
Comparison 1. 3 mg E2V on days 1-2; 2 mg DNG/2 mg E2V on days 3-7; 3 mg DNG/2 mg E2V on days 
8-24; 1 mg E2V on days 25-26; and placebo on days 27-28 versus 100 µg LNG/20 µg EE on days 1-21 and 
placebo on days 22-28




Statistical method Effect size
1 Pregnancy 1 798 Risk Ratio  
(M-H, Random, 95% CI)
0.33 [0.01, 8.16]
2  Proportion of women with intra-
cyclic bleeding at cycle 1
1 784 Risk Ratio  
(M-H, Random, 95% CI)
1.09 [0.81, 1.47]
3  Proportion of women with intra-
cyclic bleeding at cycle 2
1 780 Risk Ratio  
(M-H, Random, 95% CI)
1.38 [0.97, 1.97]
4  Proportion of women with intra-
cyclic bleeding at cycle 3
1 773 Risk Ratio  
(M-H, Random, 95% CI)
0.92 [0.64, 1.31]
5  Proportion of women with intra-
cyclic bleeding at cycle 4
1 762 Risk Ratio  
(M-H, Random, 95% CI)
1.45 [1.01, 2.10]
6  Proportion of women with intra-
cyclic bleeding at cycle 5
1 748 Risk Ratio  
(M-H, Random, 95% CI)
1.06 [0.70, 1.61]
7  Proportion of women with intra-
cyclic bleeding at cycle 6
1 746 Risk Ratio  
(M-H, Random, 95% CI)
1.06 [0.69, 1.62]
8  Proportion of women with intra-
cyclic bleeding at cycle 7
1 743 Risk Ratio  
(M-H, Random, 95% CI)
1.26 [0.84, 1.88]
9  Number of intracyclic  
bleeding episodes at cycle 1
1 784 Mean Difference  
(IV, Random, 95% CI)
0.0 [-0.07, 0.07]
10  Number of intracyclic  
bleeding episodes at cycle 2
1 780 Mean Difference  
(IV, Random, 95% CI)
0.1 [0.04, 0.16]
11  Number of intracyclic  
bleeding episodes at cycle 3
1 773 Mean Difference  
(IV, Random, 95% CI)
0.0 [-0.06, 0.06]
12  Number of intracyclic  
bleeding episodes at cycle 4
1 762 Mean Difference  
(IV, Random, 95% CI)
0.1 [0.04, 0.16]
13  Number of intracyclic  
bleeding episodes at cycle 5
1 748 Mean Difference  
(IV, Random, 95% CI)
0.0 [-0.06, 0.06]
14  Number of intracyclic  
bleeding episodes at cycle 6
1 746 Mean Difference  
(IV, Random, 95% CI)
0.0 [-0.05, 0.05]
15  Number of intracyclic  
bleeding episodes at cycle 7
1 743 Mean Difference  
(IV, Random, 95% CI)
0.0 [-0.05, 0.05]
16  Proportion of women with 
withdrawal bleeding at cycle 1
1 784 Risk Ratio  
(M-H, Random, 95% CI)
0.88 [0.83, 0.94]
17  Proportion of women with 
withdrawal bleeding at cycle 2
1 780 Risk Ratio  
(M-H, Random, 95% CI)
0.84 [0.79, 0.89]
18  Proportion of women with 
withdrawal bleeding at cycle 3
1 773 Risk Ratio  
(M-H, Random, 95% CI)
0.88 [0.83, 0.93]
19  Proportion of women with 
withdrawal bleeding at cycle 4
1 762 Risk Ratio  
(M-H, Random, 95% CI)
0.90 [0.85, 0.95]
20  Proportion of women with 
withdrawal bleeding at cycle 5
1 748 Risk Ratio  




21  Proportion of women with 
withdrawal bleeding at cycle 6
1 746 Risk Ratio  
(M-H, Random, 95% CI)
0.89 [0.84, 0.94]
22  Proportion of women with 
withdrawal bleeding at cycle 7
1 743 Risk Ratio  
(M-H, Random, 95% CI)
0.87 [0.82, 0.92]
23  Number of bleeding/spotting 
days in reference period 1
1 798 Mean Difference  
(IV, Random, 95% CI)
-4.20 [-5.52, -2.88]
24  Number of bleeding/spotting 
days in reference period 2
1 798 Mean Difference  
(IV, Random, 95% CI)
-2.5 [-3.65, -1.35]
25  Number of bleeding/spotting 
episodes in reference period 1
1 798 Mean Difference  
(IV, Random, 95% CI)
-0.40 [-0.56, -0.24]
26  Number of bleeding/spotting 
episodes in reference period 2
1 798 Mean Difference  
(IV, Random, 95% CI)
-0.10 [-0.26, 0.06]
27  Number of women discon- 
tinuing due to adverse effects
1 798 Risk Ratio  
(M-H, Random, 95% CI)
1.0 [0.47, 2.13]
28  Number of women reporting  
an adverse event
1 798 Risk Ratio  
(M-H, Random, 95% CI)
1.06 [0.84, 1.34]
29  Number of reported adverse 
events per total number of 
women
1 798 Risk Ratio  
(M-H, Random, 95% CI)
1.09 [0.92, 1.28]
30  Number of women reporting 
breast pain
1 798 Risk Ratio  
(M-H, Random, 95% CI)
3.25 [1.07, 9.88]
31  Number of women reporting 
acne
1 798 Risk Ratio  
(M-H, Random, 95% CI)
0.56 [0.19, 1.64]
32  Number of women reporting 
migraine
1 798 Risk Ratio  
(M-H, Random, 95% CI)
0.4 [0.08, 2.05]
33  Number of women reporting 
headache
1 798 Risk Ratio  
(M-H, Random, 95% CI)
1.0 [0.35, 2.82]
34  Number of women reporting 
alopecia
1 798 Risk Ratio  
(M-H, Random, 95% CI)
0.75 [0.17, 3.33]
35  Number of women reporting 
increase in body weight
1 798 Risk Ratio  
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Use of combined oral contraceptives is associated with a three- to six-fold increased risk of venous 
thrombosis. Hormonal contraceptives induce acquired resistance to activated protein C (APC), 
which predicts the risk of venous thrombosis. The biological basis of the acquired APC resistance 
is unknown. Free protein S (PS) and free Tissue Factor Pathway Inhibitor (TFPI) are the two main 
determinants APC. Our objective was to assess the effect of both hormonal and non-hormonal 
contraceptives with different routes of administration on free TFPI and free PS levels.
Methods: 
We conducted an observational study in 243 users of different contraceptives and measured APC 
sensitivity ratios (nAPCsr), free TFPI and free PS levels.
Results: 
Users of contraceptives with the highest risk of venous thrombosis as reported in recent literature, 
had the lowest free TFPI and free PS levels, and vice versa, women who used contraceptives with 
the lowest risk of venous thrombosis had the highest free TFPI and free PS levels. An association 
was observed between levels of free TFPI and nAPCsr, and between free PS and nAPCsr. 
Conclusion: 
The effect of oral contraceptives on TFPI and PS is a possible explanation for the increased risk 
of venous thrombosis associated with oral contraceptives.
49
The effect of different hormonal contraceptives on plasma levels of free protein S and free TFPI
Introduction
Use of combined oral contraceptives is associated with a three- to six-fold increased risk of 
venous thrombosis. This increased risk depends on the estrogen dose as well as the progestogen 
type of oral contraceptives (1). So called ‘high-dose’ combined oral contraceptives containing 50 
µg or more ethinylestradiol are associated with a two-fold higher risk of thrombosis than ‘low-
dose’ combined oral contraceptives containing 20 to 30 µg ethinylestradiol (2;3). Further, third-
generation combined oral contraceptives, containing the progestogens gestodene or desogestrel, 
and combined oral contraceptives containing cyproterone acetate or drospirenone increase the 
risk of venous thrombosis by a factor of two compared with combined oral contraceptives con-
taining levonorgestrel (1;3;4).
Use of combined oral contraceptives causes changes in procoagulant, anticoagulant and fibrin-
olytic parameters (5). The thrombin generation-based APC resistance test is a global assay that 
is sensitive to the levels of individual clotting factors and combines these into a net effect (6-8). 
In line with epidemiological observations, users of ‘high risk’ combined oral contraceptives con-
taining desogestrel, cyproterone actetate and drospirenone have been found more resistant to 
the anticoagulant action of APC in this test than users of ‘low risk’ combined oral contraceptives 
containing levonorgestrel. (3;4;6;8-11).
The two main determinants of the thrombin generation-based APC resistance test are free protein 
S (PS) and free tissue factor (TF) pathway inhibitor (TFPI) (12-14). The differences in APC-resis-
tance induced by oral contraceptives can at least in part be explained by different effects on free 
PS and free TFPI levels (12). 
TFPI is a Kunitz-type protease inhibitor that down-regulates the extrinsic (TF-induced) coagula-
tion pathway. It is mainly synthesized by endothelium cells (15). Approximately 80% of intra-
vascular TFPI is bound to the vessel wall, whereas 20% circulates in plasma. Only 10% (~0.25 
nM) of TFPI in plasma circulates as free full length TFPI, which is the most active form. TFPI 
down-regulates thrombin generation by inhibiting activated factor X (FXa) via the formation of a 
TFPI/FXa complex which subsequently inhibits the TF/activated factor VII (TF/FVIIa) complex by 
forming an inactive TFPI/FXa/TF/FVIIa quaternary complex (16). TFPI is a slow inhibitor of throm-
bin generation, which is most effective at low TF concentrations or when thrombin generation is 
slowed down through the intrinsic pathway (17). 
PS is a vitamin K dependent protein which acts as a non-enzymatic cofactor of APC in the prote-
olytic inactivation of the activated factors Va (FVa) and VIIIa (FVIIIa) (18). It is synthesized in the 
liver and in endothelial cells. Approximately 60% of the PS in plasma is bound to C4b Binding 
Protein (C4BP) in a high affinity complex, while the remaining 40% circulates in plasma in a free 
form. It was recently discovered that, besides its co-factor function with APC, free PS forms a 
complex with TFPI and stimulates formation of the TFPI/FXa complex, thus enhancing the down-
regulation of thrombin generation by TFPI (17;19-23). 
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Both hereditary and acquired PS deficiency is associated with an increased risk of venous throm-
bosis (20;21;21). It was observed by Castoldi et al. that PS deficient individuals also have decreased 
TFPI levels, probably due to common mechanisms regulating biosynthesis of both proteins (20). 
Van Vliet et al. (12) observed that women using combined oral contraceptives with the highest 
risk of venous thrombosis (e.g. containing desogestrel, cyproterone actetate or drospirenone), 
have lower levels of protein S and TFPI than women using the combined oral contraceptive with 
the lowest risk of venous thrombosis (i.e. contraceptives containing levonorgestrel).
The aim of this study was to assess if the different risks of venous thrombosis caused by different 
hormonal and non-hormonal methods of contraception with various routes of administration are 
reflected in the levels of APC resistance, and free TFPI and free PS, the main determinants of the 
thrombin generation-based APC resistance test.
Material and Methods
Study design and participants
We conducted an observational study. In a series of four different studies we collected samples 
of users of different hormonal and non-hormonal contraceptives, including oral, transdermal 
and vaginal combined hormonal contraceptives, the levonorgestrel-releasing intrauterine device 
(IUD), the copper-releasing IUD and female non-users with regular, ovulatory menstrual cycles 
(24-27). 
Inclusion criteria of all participants were: healthy women using a hormonal contraceptive for 
at least three cycles. Exclusion criteria were age <18 years, and contraindications for combined 
hormonal contraceptive use as stated by the World Health Organization (28). A more detailed 
description of the studies can be found in the original articles (24;26;27;29).
In total, we excluded 73 participants out of 316 eligible participants. Participants who were carri-
ers of the factor V Leiden or the prothrombin 20210A mutation were excluded from the analysis, 
because these mutations affect resistance to APC (n = 31). Users of oral contraceptives contain-
ing 20 µg ethinylestradiol and groups with a small sample size were excluded: users of the 
vaginal ring containing ethinylestradiol and etonogestrel (n = 4), users of the transdermal patch 
containing ethinylestradiol and norelgestromine (n = 3), users of a combined oral contraceptives 
containing 100 µg levonorgestrel and 20 µg ethinylestradiol (n = 4), 150 µg desogestrel and 
20 µg ethinylestradiol (n = 12), 75 µg gestodene and 20 µg ethinylestradiol (n = 7), 75 µg 
gestodene and 30 µg ethinylestradiol (n = 3), 250 µg norgestimate and 35 µg ethinylestradiol 
(n = 1) or containing 1 mg norethisterone and 35 µg ethinylestradiol (n = 2). Six participants were 
excluded because their data were not complete.
In our final analysis, we used the samples of 243 participants: 153 users of a combined oral contracep-
tive containing ethinylestradiol and levonorgestrel, desogestrel, cyproterone actetate or drospirenone, 
60 users of the levonorgestrel-IUD, 17 users of the copper-IUD and 13 non-users (mid-cycle). 
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Written informed consent was given by all participants and the studies were all approved by the 
Medical Ethics Committee of the Leiden University Medical Center, The Netherlands.
Laboratory methods
The samples from the studies were drawn, processed and stored identically. Blood samples were 
taken from the antecubital vein in the morning in a fasting state and collected in 0.106 M sodium 
citrate (pH 5.8). Cell-free, citrated plasma was prepared by centrifuging blood at 2,100 g for 10 
minutes at 18ºC, coded and centrally stored at -80 ºC. 
Protein S
Free Protein S was determined by ELISA according to Giri et al. (30) with modifications as follows: 
microtiter plates were coated overnight at 4-8 ºC with purified C4BPß (3,5 µg/mL in 0.1 M NaHCO3, 
0.5 M NaCl buffer, pH 9). Wells were washed four times with buffer A (0.05 M Tris-HCl, 0.1 M NaCl, 
0.1% Tween, 0.05% ovalbumin, pH 7,5) and incubated with buffer A containing 2,5% ovalbumin 
for 1 hour at 37 ºC to reduce background absorbance. After four washes with buffer B (0.05 M 
Tris-HCl, 0.1 M NaCl, 0,1% Tween, 0.05% ovalbumin, 0.005 M CaCl2, 0.01 M benzamidine-HCl, pH 
7,5) the dilutions of calibrator (1/10-1/640) and test samples (1/20 and 1/40) were added and 
incubated for 15 minutes at room temperature. After four washes with buffer B, HRP-conjugated 
anti-human protein S (0.4 µg/mL) antibody was added and incubated for 1 hour at 37 ºC followed 
by four washes with buffer B. Subsequently, TMB (0.2 mg/mL) and H2O2 (0.01%) were added and 
incubated for 15 minutes at room temperature, after which the reaction was stopped by adding 
4N H2SO4 and the absorbance at 450 nm was measured. Supernatant of PNP supplemented with 
an equal volume of 10% PEG 6000 was used as calibrator. This plasma contained 0.28 U/mL of 
protein S total, which is all free protein S. All sample dilutions were prepared within 10 minutes 
of starting the assay. Pooled normal plasma contained 0.31 U/mL free protein S and 1.0 U/mL 
total protein S. Inter- and intra-assay variability was 5.7% and 8.0% respectively.
TFPI
Free TFPI and total TFPI were assayed with commercial enzyme-linked immunosorbent assays 
(Asserachrom® free TFPI and Asserachrom® Total TFPI, Diagnostica Stage, Asnière, France) as 
described in detail elsewhere (31). Freeze-dried human plasmas containing known amounts of 
TFPI provided in the kits were used for calibration. Quality controls were performed using a 
control specimen containing a high amount of TFPI as well as a sample with normal level of TFPI. 
Inter- and intra-assay variability, measured as coefficients of variation, was 6,0% and 2,6% for 
total TFPI, and 9,5% and 5,3% for free TFPI, respectively. 
APC resistance
Normalized APC sensitivity ratios (nAPCsr) were determined in duplicate by quantifying the 





In this observational study, we used means, mean differences, 95% confidence intervals of the 
mean and ranges to describe variables. Scatter diagrams and regression lines were constructed 
and a regression coefficient with 95% CI was estimated with free PS or free TFPI as independent 
variable and nAPCsr as dependent variable. A bar diagram was constructed to visualize the associ-
ation between the risk of venous thrombosis during use of hormonal contraceptives as described 
in recent literature and the measured free TFPI and free PS levels. Statistics were computed using 
SPSS for Windows, version 17.0 (SPSS Inc., Chicago, IL, USA).
Results
There were no differences in BMI and age between the women using different kinds of hormonal 
contraceptives (Table 1).
Table 1: Characteristics of participants after exclusion
Contraceptive Progestogen Estrogen n Age (years) BMI (kg/m2)
Mean Range Mean Range
None - - 13 29 20-48 22 19-26
Cu-IUD - - 17 33 20-45 24 18-32
LNG-IUD 20 µg/day LNG - 60 33 17-52 25 18-48
Oral contraceptive 150 µg/day LNG 30 µg/day EE 70 29 18-51 23 17-38
Oral contraceptive 150 µg/day DSG 30 µg/day EE 16 31 18-49 25 20-32
Oral contraceptive 3 mg/day DRSP 30 µg/day EE 46 29 18-47 24 18-34
Oral contraceptive 2 mg/day CPA 35 µg/day EE 21 28 19-44 22 19-26
Total 243 30 17-52 24 17-48
 
Free TFPI levels during use of hormonal contraceptives compared with non-use
Women using the levonorgestrel-IUD had higher free TFPI levels than non-users (5.48 ng/ml 
versus 4.62 ng/ml; difference 0.85 ng/ml, 95% CI 0.05 to 1.66). The mean free TFPI level of 
women using the copper-IUD did not differ with the mean free TFPI levels of non-users (5.06 ng/
ml versus 4.62 ng/ml; difference 0.44 ng/ml, 95% CI -0.52 to 1.39). 
Combined oral contraceptive users had lower free TFPI levels than non-users. Women using 
cyproterone actetate / ethinylestradiol had the lowest mean free TFPI level: 2.51 ng/ml, differ-
ence -2.12 ng/ml compared with non-users (95% CI -2.73 to -1.50). (Table 2)
Free PS levels during use of hormonal contraceptives compared with non-use
Women using the levonorgestrel-IUD had similar free PS levels as non-users (0.28 U/dl versus 
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0.28 U/dl; MD -0.001 U/dl, 95% CI -0.03 to 0.03). The mean free PS levels of women using the 
copper-IUD did also not differ from non-users (0.26 U/dl versus 0.28 U/dl; MD -0.02 U/dl 95% CI 
-0.07 to 0.02).
Women using combined oral contraceptives had lower free PS levels than non-users. The lowest 
mean free PS levels were measured in women using cyproterone actetate / ethinylestradiol: 0.19 
U/dl , MD -0.09 U/dl compared with non-users (95% CI -0.12 to -0.05). (Table 3)
Free TFPI and free PS levels compared with levonorgestrel / ethinylestradiol
Women using combined oral contraceptives with a high risk of venous thrombosis had lower free 
TFPI levels than women using combined oral contraceptives with a lower risk of venous thrombosis, 
e.g levonorgestrel / ethinylestradiol. The mean difference between levonorgestrel / ethinylestradiol 
compared with other oral contraceptive users was -1.01 ng/ml (95% CI -1.81 to -0.22) for des-
ogestrel / ethinylestradiol, -0.57 ng/ml (95% CI -1.10 to -0.03) for drospirenone / ethinylestradiol 
and -1.42 ng/ml (95% CI -2.12 to -0.72) for cyproterone actetate / ethinylestradiol. 
The same pattern was observed for free PS levels: the mean difference in free PS of levonorg-
estrel / ethinylestradiol compared with desogestrel / ethinylestradiol was -0.09 U/dl (-0.12 to 
-0.05), compared with drospirenone / ethinylestradiol was -0.08 U/dl (95% CI -0.11 to -0.06) and 
compared with cyproterone actetate / ethinylestradiol was -0.13 U/dl (-0.16 to -0.10).
Association between free TFPI and APC resistance and free PS and APC resistance
In previous reports (33;34) on the resistance to APC in the same study population, we observed 
higher nAPCsr in the groups of women using combined oral contraceptives containing des-
ogestrel, drospirenone and cyproterone actetate than in non-users. The nAPCsr in women using 
the levonorgestrel-IUD was decreased compared with non-users and users of the combined oral 
contraceptive containing levonorgestrel / ethinylestradiol (24).  
Free TFPI levels were negatively correlated with the nAPCsr: a linear association was observed 
with the equation free TFPI = 6.082 – 0.629 * nAPCsr. Thus, a decrease of free TFPI with 1 ng/ml 
was associated with an increase of nAPCsr with 0.629 (95% CI 0.47 to 0.79). 
Free PS levels were also negatively associated with the nAPCsr: a linear association was found 
with the equation free PS = 0.355 – 0.028 * nAPCsr: when free PS levels decreased with 1 U/dl 
nAPCsr increased with 0.028 (95% CI 0.022 to 0.34).
Risk ranking per contraceptive
For risk ranking, we used recent publications from van Hylckama Vlieg et al. (3;35) (Table 4). 
The odds ratio for venous thrombosis during use of the levonorgestrel-IUD compared with non-
users was 0.3 (95% CI 0.1 to 1.1) (35). The risk of venous thrombosis during use of a copper-IUD 
is unknown, but expected not to be increased compared with non-users.
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Free TFPI levels measured in this study are associated with the odds ratios reported in recent 
literature i.e lower free TFPI levels were present in users of contraceptives with a higher risk of 
venous thrombosis. Free PS showed a less pronounced, but similar pattern (Figures 1 and 2).
Total TFPI
Total TFPI levels in plasma of users of different kinds of contraceptives were comparable. 
No association was observed between known risk ratios and total TFPI levels (data not shown).
Discussion
In this study on the effect of different contraceptives on the two main determinants of the throm-
bin generation-based APC resistance test, we observed that different doses of ethinylestradiol 
and different types of progestogens have different effects on the plasma levels of free TFPI and 
free PS. Women who are according to recent literature exposed to the highest risk of venous 
thrombosis during use of hormonal contraceptives (i.e. users of combined oral contraceptives con-
taining drospirenone / ethinylestradiol, cyproterone actetate / ethinylestradiol or desogestrel / 
ethinylestradiol), had the lowest free TFPI and free PS levels and vice versa: women who used 
hormonal contraceptives with the lowest risk of venous thrombosis (i.e. users of the levonorg-
estrel-IUD) had the highest free TFPI and free PS levels. An association was observed between 
free TFPI and nAPCsr, and between free PS and nAPCsr. 
The observed effect of different types of oral contraceptives on free TFPI are consistent with a study 
by Alhenc-Gelas et al. (37). Plasma levels of free TFPI were found to be more decreased in women 
using oral contraceptives containing desogestrel / ethinylestradiol or cyproterone actetate / ethi-
nylestradiol than in women using oral contraceptives containing levonorgestrel / ethinylestradiol. 
Several studies observed that third generation oral contraceptives containing gestodene or des-
ogestrel combined with ethinylestradiol induce a larger decrease of free PS than oral contraceptives 
containing levonorgestrel / ethinylestradiol (38-40). In our study similar decreases in free PS levels 
were found for desogestrel / ethinylestradiol users compared with levonorgestrel / ethinylestradiol 
users. In a trial by Kluft et al. (41), oral contraceptives containing drospirenone / ethinylestradiol and 
oral contraceptives containing desogestrel / ethinylestradiol led to similar reductions in PS total 
antigen levels and PS activity levels, but no data are available on free PS levels. No studies have 
been published on the effect of cyproterone actetate / ethinylestradiol on free PS levels .
In our study, sample sizes of the groups of users of the vaginal ring containing ethinylestradiol and 
etonogestrel and users of the transdermal patch containing ethinylestradiol and norelgestromine 
were too small for analysis. In a randomized controlled trial by Johnson et al. (42) patch users had 
lower free PS levels than users of a levonorgestrel / ethinylestradiol containing oral contracep-
tive. Jensen et al. (43) found that free PS levels of ring users were higher, and free PS levels of 
patch users were lower compared with use of a combined oral contraceptive. Recently, Lidegaard 
et al. (36) reported a RR of 7.9 (95% CI 3.5 to 17.6) for users of the transdermal patch and a RR of 
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6.5 (95% CI 4.7 to 8.9) for users of the vaginal ring compared with non-users. Both contraceptives 
contain an estrogen and a progestogen compound and work systemically. Increased relative risks 
were observed, so decreased levels of TFPI and PS are to be expected. 
The use of the levonorgestrel-IUD is not associated with an increased risk of venous thrombosis 
(35;44). In this study, women using the levonorgestrel-IUD had higher free TFPI and similar free 
PS and nAPCsr levels as non-users, indicating that use of the levonorgestrel-IUD is not associ-
ated with an increased risk of venous thrombosis. It can be hypothesized that the differences in 
free TFPI levels are attributable to the progestogen compound of the hormonal contraceptive, 
since the amount of ethinylestradiol of hormonal contraceptives used in this study were similar 
while the progestogen types differed, and different levels of free TFPI were observed. Possibly, 
progestogens cause an increase in free TFPI, as observed in users of the levonorgestrel-IUD, and 
ethinylestradiol causes a decrease in free TFPI, reflected as a net effect. No other studies have 
been published on free PS and free TFPI levels in users of the levonorgestrel-IUD or copper-IUD.
Kemmeren et al. explained the differences in free PS induced by various oral contraceptives by 
the interaction between PS and C4BP. C4BP binds protein S in a high affinity complex (39). They 
observed that total PS was decreased by oral contraceptives containing desogestrel / ethinylestra-
diol but was hardly affected by oral contraceptives containing levonorgestrel / ethinylestradiol 
and that both oral contraceptives equally lowered C4BP. As a result, free PS levels increase in 
users of levonorgestrel / ethinylestradiol and decrease in users of desogestrel / ethinylestradiol.
Free PS forms a complex with free TFPI and acts as cofactor of TFPI through the extrinsic pathway 
(17;19-22). Inherited or acquired PS deficiency causes concomitant decreased free TFPI levels (20). A 
possible explanation could be that binding of free TFPI to free PS protects it from proteolytic degrada-
tion or slows down the clearance of free TFPI. So a decrease of free PS will then be accompanied by 
a decrease in free TFPI. The effect of hormonal contraceptives on free PS is probably only part of the 
mechanism of the increased risk of venous thrombosis since the effect on free TFPI-levels is usually 
larger than the effect on free PS. Due to this fact it is likely that TFPI production or release is also 
influenced by hormonal contraceptives; both proteins share the endothelium as common production 
site. In addition, the secretion of TFPI from endothelial cells might be coupled to PS secretion, as has 
recently been discovered for PS and the beta chain of C4BP by Carlsson et al. (20;45). 
In conclusion, we observed that users of the levonorgestrel-IUD have similar levels of free PS and 
higher levels of free TFPI as non-users. Users of oral contraceptives containing drospirenone / 
ethinylestradiol, cyproterone actetate / ethinylestradiol and desogestrel / ethinylestradiol had 
lower free TFPI and free PS levels than users of oral contraceptives containing levonorgestrel / 
ethinylestradiol. A negative association between the thrombotic risks as reported in recent lit-
erature and free PS and free TFPI levels was observed. Our study confirms the hypothesis that 
the differences in APC resistance induced by hormonal contraceptives can be partly explained 
by different effects on free TFPI and free PS levels. Future studies are indicated to unravel the 
mechanism of the reduction of free PS and free TFPI during use of hormonal contraceptives and 
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It takes many years to obtain reliable values for the risk of venous thrombosis of hormonal 
contraceptive users from clinical data. Measurement of activated protein C (APC) resistance via 
thrombin generation is a validated test for determining the thrombogenicity of hormonal con-
traceptives. Sex hormone-binding globulin (SHBG) might serve as a marker for the risk of venous 
thrombosis, and can be easily and rapidly measured in routine laboratories. 
Objective:
To determine whether SHBG is a useful marker for the thrombotic risk of hormonal contraceptive 
users by comparing plasma SHBG levels with normalized APC sensitivity ratio (nAPCsr) values and 
thrombosis risks reported in the recent literature. 
Methods:
We conducted an observational study in 262 users of different contraceptives, and measured 
nAPCsr and SHBG levels. 
Results: 
Users of contraceptives with a higher risk of causing venous thrombosis, i.e. combined hor-
monal  contraceptives containing desogestrel, cyproterone acetate or drospirenone, and 
the transdermal patch, had higher SHBG levels than users of combined hormonal contracep-
tives containing levonorgestrel, which carry a lower thrombosis risk. Users of the patch had 
the highest SHBG levels, with a mean difference of 246 nmol/L (95% confidence interval 
179–349) from that in users of levonorgestrel-containing combined hormonal contraceptives. 
SHBG levels were positively associated with both the nAPCsr and the risks of venous thrombosis 
reported in the recent literature.
Conclusion: 
SHBG is a useful marker with which to estimate the thrombotic safety of a preparation. 
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Introduction
The use of combined oral contraceptives is associated with a three-fold to six-fold increased 
risk of venous thrombosis (1). This increased risk depends on both the estrogen dose and the 
progestogen type of combined oral contraceptives (1). So-called ‘high-dose’ combined oral 
contraceptives containing 50 µg or more ethinylestradiol (EE) are associated with a two-fold 
higher risk of thrombosis than ‘low-dose’ combined oral contraceptives containing 20–30 µg 
of EE (2;3). Furthermore, combined oral contraceptives containing the progestogens gestodene 
(GTD), desogestrel (DSG), cyproterone acetate (CPA) or drospirenone (DRSP) increase the risk of 
venous thrombosis by a factor of two as compared with combined oral contraceptives containing 
levonorgestrel (LNG) (1–13).
The differences in the risk of venous thrombosis can be at least partially explained by the 
association of various combined oral contraceptives with differences in resistance to activated 
protein C (APC) as measured with the thrombin generation-based APC resistance test and quanti-
fied via a normalized APC sensitivity ratio (nAPCsr) (14–16). High nAPCsr indicates increased APC 
resistance, which is a risk factor for venous thrombosis. Thrombin generation-based APC resis-
tance has been validated in a case–control study by Tans et al. (17), and predicts the risk of venous 
thrombosis in users of combined oral contraceptives, as well as in non-users and men, with or 
without the factor V Leiden mutation. The highest odds ratio (OR) of venous thrombosis in the 
absence of the FV Leiden mutation was observed in premenopausal women using combined oral 
contraceptives, lending support to the hypothesis that the prothrombotic effect of combined oral 
contraceptives is the result of acquired APC resistance in a thrombin generation-based test (17). 
Users of combined oral contraceptives with a higher risk of causing venous thrombosis, e.g. those 
containing DSG, CPA or DRSP, have been found to be more resistant to the anticoagulant action of 
APC than users of combined oral contraceptives with a lower risk of causing venous thrombosis, 
i.e. those containing LNG (3;6;9;10;14–16).
As the absolute risk of venous thrombosis in women using combined oral contraceptives is low, 
i.e. three to four per 10 000 woman-years (1), the assessment of differences in risk between an 
existing and a new preparation requires hundreds of thousands of users. This sample size makes a 
clinical study of a new hormonal contraceptive before market authorization almost impossible. 
In a search for other markers that can predict the risk of venous thrombosis in users of hormonal 
contraceptives, Odlind et al. (18) postulated sex hormone-binding globulin (SHBG) as a marker 
for estrogenicity of a contraceptive preparation and possibly for the risk of venous thrombosis. 
SHBG is a carrier protein that is produced in the liver and binds estrogen and testosterone (19). 
The hypothesis is that estrogens cause a dose-related increase in SHBG levels, whereas progesto-
gens induce a decrease in SHBG levels, dependent on both the dose and the type of progestogen 
(20–22). The type-related differences in the progestogen-induced decrease in SHBG levels can 
be interpreted as differences in the antiestrogenic properties of progestogens. Thus, the effect 
of a hormonal contraceptive on SHBG is the combined result of the estrogenic effect of EE and 
the antiestrogenic effect of the progestogen, yielding the total estrogenicity of that hormonal 
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contraceptive. This estrogenicity might serve as a marker for venous thrombosis. Several studies 
have shown an association between the risk of causing venous thrombosis of combined oral con-
traceptives, APC resistance, and SHBG levels (1–3;15;23). 
To investigate whether SHBG is a useful marker for the risk of venous thrombosis of combined oral 
contraceptives, we determined SHBG levels in non-users and in users of different contraceptives, 
both hormonal and non-hormonal, and compared the SHBG levels with nAPCsr as determined via 
thrombin generation and with the risks of venous thrombosis as reported in the literature.
Materials and methods
Study design and participants
We conducted an observational study. In a series of four different studies, we included users of 
various hormonal and non-hormonal contraceptives (15;24–26). Users of different combined hor-
monal contraceptives, including oral, transdermal and vaginal combined hormonal contraceptives, 
users of LNG-releasing intrauterine devices (IUDs) (LNG-IUDs), users of copper-releasing IUDs 
(Cu-IUDs) and healthy female non-users with regular, ovulatory menstrual cycles were studied.
The inclusion criterion for all participants was as follows: healthy women using a hormonal con-
traceptive for at least three cycles. Exclusion criteria were age < 18 years, and contraindications 
for combined hormonal contraceptive use as stated by the World Health Organization (27). A more 
detailed description can be found in the original articles (15;24–26). 
Participants who were carriers of the FV Leiden mutation were excluded from the analysis, 
because this mutation causes resistance to APC without affecting SHBG levels (n = 30). The fol-
lowing data were not used because of a small sample size: users of a combined oral contraceptive 
containing GTD, norgestimate and norethisterone (n = 3 for GTD, n = 1 for norgestimate, and n = 
2 for norethisterone). Furthermore, we only used data from users of combined oral contraceptives 
containing 30–35 µg of EE; users of preparations with other amounts of EE were excluded (n = 
24). For 26 participants, data were not complete, so they were excluded. In total, we excluded 86 
participants. 
In our final analysis, we used the samples of 262 participants: 159 users of a combined oral con-
traceptive (containing 30–35 µg of EE and LNG, DSG, CPA, or DRSP), 60 users of the LNG-IUD, 17 
users of the Cu-IUD, seven users of the transdermal patch (containing EE and norelgestromine 
(NGM)), six users of the vaginal ring (containing EE and etonogestrel (ENG)), and 13 non-users 
(mid-cycle). 
Written informed consent was given by all participants, and the studies were all approved by 
theMedical Ethics Committee of the Leiden University Medical Center, The Netherlands.
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Laboratory methods
The plasma samples from the studies were taken, processed and stored identically. Blood 
samples were taken from the antecubital vein in the morning in a fasting state, and collected in 
0.106 mol/L sodium citrate (pH 5.8). Cell-free, citrated plasma was prepared by centrifuging blood 
at 2.100 g for 10 min at 18 °C, coded, and centrally stored at - 80 °C. 
SHBG (nmol/L) was measured with an immunometric assay (Immulite 2000 XPi; Siemens Health-
care Diagnostics, Tarrytown, NY, USA). The sensitivity is 0.2 nmol/L, and has a long-term variation 
of 6%, at levels of both 5 and 80 nmol/L The within-assay variation is 3–4%, and the between-
assay variation is 3.5–6%. APC resistance was measured with the thrombin generation-based APC 
resistance test, as described previously (14).
nAPCsr values of plasma samples from women using an LNG-IUD or a Cu-IUD were originally 
measured with a variant of the thrombin generation-based APC resistance assay, by the use of 
using calibrated automated thrombinography (24;28). As nAPCsr values determined with cali-
brated automated thrombinography are higher than those determined with the classical end-
point method (16;29), the plasma samples from IUD users were reanalyzed with the endpoint 
method. 
SHBG levels and APC resistance in non-users during midcycle were used in the analysis. The dif-
ferent phases in the menstrual cycle were defined by repeated measurements of progesterone 
and estradiol levels; mid-cycle is defined as the time when estradiol levels are high and proges-
terone levels are low.
Statistical analysis
We used means, mean differences, 95% confidence intervals and ranges to describe variables. We 
constructed a scatterplot to describe the association between SHBG levels and nAPCsr; in this 
figure SHBG data were logarithmically transformed to create normality and a histogram analysis 
of the residuals was performed to check whether this assumption is valid. A regression analysis 
was performed to describe the association.
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Table 1: Body mass index (BMI) and age of the research population
Contraceptive n BMI (kg m-2) Age (years)
Mean Range Mean Range
None 13 21.7 19–29 29.0 20–48
LNG-IUD 60 24.5 18–47 32.6 17–52
Cu-IUD 17 24.2 18–32 32.4 20–45
LNG/EE 72 22.2 17–38 25.7 18–51
DSG/EE 18 24.0 20–32 30.2 18–49
DRSP/E 22 22.1 19–26 27.5 19–44
CPA/EE 22 22.1 19–26 27.5 19–44
ENG/EE (ring) 6 24.2 21–28 26.4 20–36
NGM/EE (patch) 7 22. 4 20–26 31.1 25–43
All 262 23.5 18–47 28.8 17–52
CPA, cyproterone acetate; Cu-IUD, copper-releasing intrauterine device; EE, ethinylestradiol; ENG, 
etonogestrel; DRSP, drospirenone; DSG, desogestrel; LNG, levonorgestrel; LNG-IUD, levonorgestrelre-
leasing intrauterine device; NGM, norelgestromine.
Fig. 1. Sex hormone-binding globulin (SHBG) levels and their 95% confi dence intervals (CIs) by con-
traceptive type. CPA, cyproterone acetate;Cu-IUD, copper-releasing intrauterine device; DRSP, 
drospirenone;DSG, desogestrel; EE, ethinylestradiol; ENG, etonogestrel; LNG, levonorgestrel; LNG-IUD, 















None Cu-IUD LNG/EE DSG/EE DRSP/EE CPA/EE ETN/EE NGM/EE
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Table 2: Mean sex hormone-binding globulin (SHBG) and activated protein C (APC) resistance levels, 
mean differences (MDs) and 95% confi dence intervals (CIs) for non-users as compared with levonorgestrel 
(LNG)/ethinylestradiol (EE) users
Fig. 2. The association between sex hormone-binding globulin (SHBG) and activated protein C (APC) 








Contraceptive n SHBG (nmol L-1) APC-resistance (ratio)
Compared to non-use Compared to LNG/EE  Compared to non-use
Mean MD 95% CI MD 95% CI Mean MD 95% CI
None 13 53.22 Ref -17.78 -41.35 to 5.44 1.54 Ref
LNG-IUD 60 43.77 -9.45 -22.08 to 3.17 -27.23 -39.03 to -15.44 0.85 -0.69 -1.03 to -0.36
Cu-IUD 17 57.52 4.29 -7.26 to 15.85 -13.48 -34.00 to 7.03 1.03 -0.51 -0.93 to -0.09
LNG/EE 72 71.00 17.78 -5.46 to 41.02 Ref 2.66 1.12 0.69 to 1.54
DSG/EE 18 162.78 109.55 82.98 to 136.13 91.78 69.60 to 113.96 3.94 2.40 1.93 to 2.86
DRSP/EE 47 161.04 107.82 7.10 to 139.54 90.04 72.23 to 107.85 3.53 1.98 1.49 to 2.48
CPA/EE 22 210.27 157.05 121.03 to 193.07 139.27 116.41 to 162.13 4.00 2.46 2.07 to 2.84
ENG/EE  (Ring) 6 258.93 205.71 104.77 to 306.65 187.93 136.51 to 239.36 3.02 1.47 0.94 to 2.02
NGM/EE  (Patch) 7 317.57 264.35 179.63 to 349.06 246.57 201.29 to 291.85 3.12 1.57 0.87 to 2.28
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Fig. 3. The association between odds ratios (ORs) of the risk of venous thrombosis of various contracep-
tives as published in the recent literature [3,31,32] and sex hormone-binding globulin (SHBG) levels of 
hormonal contraceptives. CPA, cyproterone acetate; DRSP, drospirenone; DSG, desogestrel; EE, ethi-
nylestradiol; LNG, levonorgestrel; LNG-IUD, levonorgestrel-releasing intrauterine device.
Table 3. The odds ratios (ORs) of venous thrombosis during the use ofdifferent types of hormonal contra-
ceptive as compared with non-users,according to the recent literature [3,31,32]
Contraceptive Risk Reference
OR 95% CI
None Ref   
LNG-IUD 0.3 0.1 to 1.1 (31)
Cu-IUD - -  
LNG/EE 3.6 2.9 to 4.6 (3)
DSG/EE 7.3   5.3 to 10.0 (3)
DRSP/EE 6.3   2.9 to 13.7 (3)
CPA/EE 6.8   4.6 to 10.0 (3)
ETN/EE - -  
NGM/EE 1.3 to 2.0 - (32)
CI, confi dence interval; CPA, cyproterone acetate; Cu-IUD, copperreleasing intrauterinedevice;DRSP, dros
pirenone;DSG,desogestrel;EE, ethinylestradiol; ENG, etonogestrel; LNG, levonorgestrel; LNG-IUD, levon-
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Results
There were no significant differences in BMI and age between the women using different kinds 
of hormonal contraceptives (Table 1).
SHBG levels during contraceptive use
SHBG levels of the studied contraceptives were compared to non-users and to users of the most 
used combined oral contraceptive containing LNG/EE. Users of contraceptives containing EE plus 
CPA, DRSP or DSG and users of the transdermal patch or vaginal ring had higher SHBG levels than 
users of the LNG/EE containing combined oral contraceptive. Users of the LNG-IUD or Cu-IUD had 
lower or comparable SHBG levels as non-users. (Fig. 1, Table 2).
Association between SHBG and APC resistance
SHBG plasma levels were positively associated with nAPCsr in users of different kinds of 
hormonal contraceptives (i.e. combined oral contraceptives and LNG-IUD) and non-users. An 
exponential association was observed according the equation: log10(SHBG) = 1,525 + 0,160 × nAPCsr. 
Thus, when the nAPCsr increases with 1 unit, SHBG levels increase with 45% (100.160 = 1.45) (Fig. 2).
Risk ranking per contraceptive
For risk ranking, we used recent publications by van Hylckama Vlieg et al (3) and Jick et al (30). 
(Table 3) The observed odds ratio for venous thrombosis during use of the LNG-IUD compared 
to non-users was 0.3 (95% CI 0.1 to 1.1) (3) and the observed odds ratio during use of the 
transdermal patch compared to use of the LNG containing combined oral contraceptives was 
variable and reported to be between 1.3 and 2.0 (30). The risk of venous thrombosis during use 
of a Cu-IUD is unknown, but expected not to be increased compared to non-users. There are no 
data on the contraceptive vaginal ring compared to non-users, but a study on the risk of venous 
thrombosis of the contraceptive ring showed an 1.56 fold increased risk compared to a group of 
combined oral contraceptives with low estrogen (13).
SHBG levels measured in this study are associated with the odds ratios reported in recent 
literature: higher SHBG levels are present in users of contraceptives with a higher risk of venous 




In this study we observed positive associations between the effects of hormonal contraceptives on 
SHBG levels, the nAPCsr and the thrombotic risk reported in recent literature. High nAPCsr in the 
thrombin-generation based test indicate increased resistance to APC and is reported to be a risk factor 
for venous thrombosis (11). Together, these observations support the hypothesis that not only the 
APCsr, but also SHBG levels are a marker for the risk of venous thrombosis during the use of hormonal 
contraceptives.
The use of the LNG-IUD did not increase SHBG levels, which is in concordance with recent clinical 
data. In a national cohort study by Lidegaard et al (12), users of the LNG-IUD had no increased risk 
of thrombosis compared to non-users (RR 0.83 and 95% CI 0.63 to 1.08). This was confirmed by van 
Hylckama Vlieg et al (31) who also did not find an increased risk in a recent case-control study (OR 0.3 
and 95% CI 0.1 to 1.1).
Limited data are available on the thrombotic risk of the contraceptive transdermal patch and vaginal 
ring. Conflicting results have been reported on the thrombotic safety of the contraceptive patch with 
estimates of the thrombotic risk varying between 0.9 (95%CI 0.5 to 1.6) (32) to 2.4 (95% CI 1.1 to 5.5) 
(33) compared to oral contraceptives containing norgestimate and EE (29;30;34). 
Recently, the first study on the risk of venous thrombosis of the contraceptive ring has been published 
by the FDA (13). Use of the vaginal ring was associated with a 1.56-fold (95% CI 1.02 to 2.37) higher 
risk of thrombosis compared to a group of combined oral contraceptives with low estrogen. The study 
also observed a 1.55-fold (95% CI 1.02 to 2.37) higher thrombotic risk during use of the transdermal 
patch. In our study, users of the vaginal ring and the transdermal patch had the highest SHBG levels 
of all contraceptive users. These results are in agreement with earlier studies, reporting an increase 
in SHBG of ~260% for transdermal patch users and ~150% for vaginal ring users compared to pre-
treatment levels (18;26). The increased SHBG levels in women using the patch and ring compared to 
women using combined oral contraceptives containing LNG suggest an increased thrombotic risk. 
The increased risk of the vaginal ring might be explained by the fact that etonogestrel (ENG) is the 
active metabolite of DSG. According to recent literature, use of combined hormonal contraceptives 
containing DSG is associated with a 1.82-fold (95% CI 1.49 to 2.22) higher risk of venous thrombosis 
compared to use of combined oral contraceptives containing LNG/EE (6). However, in women using the 
contraceptive ring peak serum concentrations of EE and DSG are significantly lower than in women 
using a combined oral contraceptive containing DSG and EE (35). 
The increased risk of the transdermal patch might be explained by the 60 percent higher exposure to 
EE as measured by the area under the curve and steady state concentration during use of the contra-
ceptive patch compared to use of an oral contraceptive composed of norelgestromine (NGM) and EE. 
NGM exposure is similar during use of the contraceptive patch and pill (36;37). Since the increased 
SHBG levels in users of the patch and ring in our study are based on a small number of participants, 
further studies are indicated to confirm these results and to draw definite conclusions.
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The difference in SHBG levels between the hormone preparations was not the result of differences 
between women but rather between contraceptive methods as evidenced by the women who switched 
from one contraceptive type to another in the original studies. For example, switching from a com-
bined hormonal contraceptive containing CPA to a combined hormonal contraceptive containing LNG, 
resulted in a mean decrease of SHBG by 150 nmol/L (95% CI -206 to -94) (6;19;20).
Currently, a biological explanation for the association between the changes in SHBG and APC resis-
tance induced by hormonal contraceptives is lacking. It is known that estrogen increases the risk of 
venous thrombosis and that a higher dose is associated with a higher risk. We propose that SHBG 
reflects overall estrogenicity of a hormonal contraceptive and thereby the risk of venous thrombosis. 
SHBG and several coagulation factors and anticoagulant proteins are synthesized in the liver and 
hormonal contraceptives, which are metabolized in the liver, might interfere with the synthesis of 
both SHBG and coagulation factors. There are now different studies demonstrating an association 
between SHBG and the risk of venous thrombosis. However, the mechanism is still not known and 
further research is needed to unravel the association, changes in other proteins produced in the liver, 
changes of haemostatic parameters and the increased risk of venous thrombosis.
We acknowledge that caution is required when using surrogate markers since they can be severely 
misleading (38). Preferably, a surrogate marker should be validated in a prospective trial in which both 
the surrogate marker and the clinical endpoint are assessed. However, in case of very rare events, such 
as venous thrombosis during combined hormonal contraceptive use, a clinical study is almost unfea-
sible due to the required number of participants. In order to prospectively demonstrate a doubling of 
the risk of venous thrombosis between two different combined hormonal contraceptives with a power 
of 80% and a significance level of 5%, a cohort of approximately 500 000 women must be followed 
for one year (27). Case-control studies only become possible post-marketing (27;39). Such a large 
sample size makes it almost impossible for a pharmaceutical company to evaluate the risk of venous 
thrombosis of a new preparation before market authorization. 
There are now reasonably reliable data of the risk of venous thrombosis from several epidemiological 
studies showing that the combination of EE plus LNG carries the lowest risk of venous thrombosis of 
all combined hormonal contraceptives (1;3;5;6). Comparing the SHBG levels in users of a new prepara-
tion with that of EE plus LNG could give an estimation of the magnitude of the risk of venous throm-
bosis before a new preparation is launched and should be included in the general benefit-risk analysis 
of the new preparation. SHBG measurement is already recommended in guidelines during clinical 
development of a new combined hormonal contraceptive by the European Medicines Agency (EMA). 
In conclusion, our data support that SHBG could be a useful marker for estimating the risk of venous 
thrombosis of a new hormonal contraceptive. Preferably, the effect of a new hormonal contracep-
tive on SHBG should be compared with the effect of the combined hormonal contraceptive with 




1   Vandenbroucke JP, Rosing J, Bloemenkamp KWM, Middeldorp S, Helmerhorst FM, Bouma 
BN, Rosendaal FR. Oral contraceptives and the risk of venous thrombosis. N Eng J Med 
2001;344:1527-34.
2   Rosendaal FR, Van Hylckama Vlieg A, Tanis BC, Helmerhorst FM. Estrogens, progestogens and 
thrombosis. J Thromb Haemost 2003;1:1371-80.
3   Van Hylckama Vlieg A, Helmerhorst FM, Vandenbroucke JP, Doggen CJ, Rosendaal FR. The 
venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: 
results of the MEGA case-control study. BMJ 2009;339:b2921.
4   Bloemenkamp KW, Rosendaal FR, Helmerhorst FM, Buller HR, Vandenbroucke JP. Enhancement 
by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives 
containing a third-generation progestagen. Lancet 1995;346:1593-6.
5   Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic 
disease. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid 
Hormone Contraception. Lancet 1995;346, 1582-1588. 
6   Lidegaard O, Lokkegaard E, Svendsen AL, Agger C. Hormonal contraception and risk of venous 
thromboembolism: national follow-up study. BMJ 2009;339:b2890.
7   Jick H, Jick SS, Gurewich V, Myers MW, Vasilakis C. Risk of idiopathic cardiovascular death and 
nonfatal venous thromboembolism in women using oral contraceptives with differing progesta-
gen components. Lancet 1995;346:1589-93.
8   Van Hylckama Vlieg A, Middeldorp S. Hormone therapies and venous thromboembolism: where 
are we now? J Thromb Haemost 2011;9:257-66.
9   Jick SS, Hernandez RK. Risk of non-fatal venous thromboembolism in women using oral contra-
ceptives containing drospirenone compared with women using oral contraceptives containing 
levonorgestrel: case-control study using United States claims data. BMJ 2011;342:d2151. 
10   Parkin L, Sharples K, Hernandez RK, Jick SS. Risk of venous thromboembolism in users of oral 
contraceptives containing drospirenone or levonorgestrel: nested case-control study based on 
UK General Practice Research Database. BMJ 2011;342:d2139.
11   Gronich N, Lavi I, Rennert G. Higher risk of venous thrombosis associated with drospirenone-
containing oral contraceptives: a population-based cohort study. CMAJ 2011 ;183:E1319-E1325.
12   Lidegaard O, Nielsen LH, Skovlund CW, Skjeldestad FE, Lokkegaard E. Risk of venous throm-
boembolism from use of oral contraceptives containing different progestogens and oestrogen 
doses: Danish cohort study, 2001-9. BMJ 2011;343:d6423.
13   Combined Hormonal Contraceptives CHC’s and the Risk of Cardiovascular Disease Endpoints; 
Food and Drug Administration, http://www.fda.gov/downloads/Drugs/DrugSafety/UCM277384.
pdf,  2012.  
14   Rosing J, Middeldorp S, Curvers J, Christella M, Thomassen LG, Nicolaes GA, Meijers JC, Bouma 
BN, Buller HR, Prins MH, Tans G. Low-dose oral contraceptives and acquired resistance to acti-
vated protein C: a randomised cross-over study. Lancet 1999;354:2036-40. 
15   Van Vliet HA, Winkel TA, Noort I, Rosing J, Rosendaal FR. Prothrombotic changes in users 
of combined oral contraceptives containing drospirenone and cyproterone acetate. J Thromb 
Haemost 2004;2:2060-2. 
16   Tchaikovski SN, Van Vliet HA, Thomassen MC, Bertina RM, Rosendaal FR, Sandset PM, Helmer-
horst FM, Tans G, Rosing J. Effect of oral contraceptives on thrombin generation measured via 
calibrated automated thrombography. Thromb Haemost 2007;98:1350-6. 
73
Sex hormone-binding globulin as a marker for the thrombotic risk of hormonal contraceptives
17   Tans G, Van Hylckama Vlieg A, Thomassen MC, Curvers J, Bertina RM, Rosing J, Rosendaal FR. 
Activated protein C resistance determined with a thrombin generation-based test predicts for 
venous thrombosis in men and women. Br J Haematol 2003;122:465-70.
18   Odlind V, Milsom I, Persson I, Victor A. Can changes in sex hormone binding globulin predict the 
risk of venous thromboembolism with combined oral contraceptive pills? Acta Obstet Gynecol 
Scand 2002;81:482-90.
19   Gardner DG. Greenspan’s Basic & Clinical Endocrinology. 8th edn. New York: McGraw-Hill Com-
panies, Inc., 2007. 
20   Van der Vange N, Blankenstein MA, Kloosterboer HJ, Haspels AA, Thijssen JH. Effects of seven 
low-dose combined oral contraceptives on sex hormone binding globulin, corticosteroid binding 
globulin, total and free testosterone. Contraception 1990;41:345-52. 
21   Knopp RH, Broyles FE, Cheung M, Moore K, Marcovina S, Chandler WL. Comparison of the 
lipoprotein, carbohydrate, and hemostatic effects of phasic oral contraceptives containing des-
ogestrel or levonorgestrel. Contraception 2001;63:1-11. 
22   Kemmeren JM, Algra A, Meijers JC, Tans G, Bouma BN, Curvers J, Rosing J, Grobbee DE. Effect of 
second- and third-generation oral contraceptives on the protein C system in the absence or pres-
ence of the factor V Leiden mutation: a randomized trial. Blood 2004;103:927-33. 
23   Van Rooijen M, Silveira A, Hamsten A, Bremme K. Sex hormone-binding globulin --a surrogate 
marker for the prothrombotic effects of combined oral contraceptives. Am J Obstet Gynecol 
2004;190:332-7. 
24   Van Vliet HA, Tchaikovski SN, Rosendaal FR, Rosing J, Helmerhorst FM. The effect of the 
levonorgestrel-releasing intrauterine system on the resistance to activated protein C APC. 
Thromb Haemost 2009;101:691-5.
25   Van Vliet HA, Rodrigues SP, Snieders MN, van der Meer FJ, Frolich M, Rosendaal FR, Rosing J, 
Helmerhorst FM. Sensitivity to activated protein C during the menstrual cycle in women with 
and without factor VLeiden. Thromb Res 2008;121:757-61. 
26   Fleischer K, Van Vliet HA, Rosendaal FR, Rosing J, Tchaikovski S, Helmerhorst FM. Effects of the 
contraceptive patch, the vaginal ring and an oral contraceptive on APC resistance and SHBG: a 
cross-over study. Thromb Res 2009;123:429-35.
27   WHO. Medical eligibility criteria for contraceptive use. 4th ed. Geneva: WHO; 2009. Available 
at http://www.who.int/reproductivehealth/publications/family_planning/9789241563888/en/
index.html  2011. 
28   Tchaikovski S. Hormone-induced changes in the coagulation system. Thesis Maastricht Univer-
sity,  2009. Universitaire Pers Maastricht, Maastricht, the Netherlands. 
29   Johnson JV, Lowell J, Badger GJ, Rosing J, Tchaikovski S, Cushman M. Effects of oral and trans-
dermal hormonal contraception on vascular risk markers: a randomized controlled trial. Obstet 
Gynecol 2008;111:278-84.
30   Jick SS, Hagberg KW, Hernandez RK, Kaye JA. Postmarketing study of ORTHO EVRA and 
levonorgestrel oral contraceptives containing hormonal contraceptives with 30 mcg of ethinyl 
estradiol in relation to nonfatal venous thromboembolism. Contraception 2010;81:16-21.
31   Van Hylckama Vlieg A, Helmerhorst FM, Rosendaal FR. The risk of deep venous thrombosis asso-
ciated with injectable depot-medroxyprogesterone acetate contraceptives or a levonorgestrel 
intrauterine device. Arterioscler Thromb Vasc Biol 2010;30:2297-300.
32   Jick SS, Kaye JA, Russmann S, Jick H. Risk of nonfatal venous thromboembolism in women using 
a contraceptive transdermal patch and oral contraceptives containing norgestimate and 35 




33   Cole JA, Norman H, Doherty M, Walker AM. Venous thromboembolism, myocardial infarction, 
and stroke among transdermal contraceptive system users. Obstet Gynecol 2007;109:339-46. 
34   Jick SS, Kaye JA, Li L, Jick H. Further results on the risk of nonfatal venous thromboembolism in 
users of the contraceptive transdermal patch compared to users of oral contraceptives contain-
ing norgestimate and 35ug of ethinyl estradiol. Contraception 2007;76: 4-7
35   Timmer CJ, Mulders TM. Pharmacokinetics of etonogestrel and ethinylestradiol released from a 
combined contraceptive vaginal ring. Clin Pharmacokinet 2000 Sep;393:233-42. 
36   Ortho-McNeil-Janssen Pharmaceuticals. US Product Information Ortho-Evra®. http://www.
orthoevra.com, 2009.  
37   Devineni D, Skee D, Vaccaro N, Massarella J, Janssens L, LaGuardia KD, Leung AT. Pharmacoki-
netics and pharmacodynamics of a transdermal contraceptive patch and an oral contraceptive. J 
Clin Pharmacol 2007;47:497-509. 
38   Stanczyk FZ, Grimes DA. Sex hormone-binding globulin: not a surrogate marker for venous 
thromboembolism in women using oral contraceptives. Contraception 2008;78:201-3. 





Effect of ethinylestradiol 
dose and progestagen in 
combined oral contraceptives 
on plasma sex hormone 






Huib A.A.M. van Vliet
Frits R. Rosendaal
Astrid van Hylckama Vlieg
J Thromb Haemost 2013; 11: 203–205

79
Effect of ethinylestradiol dose and progestagen in combined oral contraceptives 
on plasma sex hormone binding globulin levels in premenopausal women
The effect of a combined oral contraceptive (COC) on sex hormone binding globulin (SHBG) levels 
may be an indicator for venous thrombosis risk of the COC involved (1;2). SHBG is a plasma glyco-
protein primarily produced in hepatocytes that binds the sex steroid hormones testosterone and 
17β-estradiol but not ethinylestradiol. Users of COC containing a third generation progestagen 
have higher SHBG levels than second generation progestagen users (1;2) reflecting the difference 
in venous thrombosis risk. In accordance with the hypothesis that SHBG levels are a marker of 
venous thrombosis risk, SHBG levels in COC users are positively associated with thrombin gener-
ation-based activated protein C resistance (APC resistance) (2). APC resistance has been shown to 
predict venous thrombosis risk in both men and women.
If SHBG levels can be considered a marker for venous thrombosis and ethinylestradiol is the main 
compound in COC causing venous thrombosis, then the ethinylestradiol dose in COC should be 
reflected in SHBG levels. The main aim of this study was to determine whether an increase in 
ethinylestradiol dose result in higher SHBG levels in healthy premenopausal women.
Participants were selected from a large case-control study on venous thrombosis, i.e., the Mul-
tiple Environmental and Genetic Assessment of risk factors for venous thrombosis (MEGA) study 
(3) and from a crossover study where women were asked to switch from their current contracep-
tive to either a COC containing drospirenone or levonorgestrel, i.e., the DRSP (drospirenone/ethi-
nylestradiol) study (2). From the MEGA study, female control subjects, i.e. women without venous 
thrombosis were selected. From the DRSP study, data of women before switching to a specific 
COC were used. We excluded women with known environmental thrombotic risk factors. A total 
of 191 healthy premenopausal women using COC were included (181 from the MEGA study and 
101 the DRSP study).
In the MEGA study, whether the women were menstruating at venipuncture was recorded; however, 
blood was drawn randomly during the four week cycle of pill use (3 weeks of pill use followed by 
a pill-free week). In the DRSP study, blood was drawn between days 18 and 21 of the four week 
cycle of pill-use. SHBG levels (nmol/L) were measured with an immunometric assay (Immulite; 
Siemens Healthcare Diagnostics, Tarrytown, NY, USA) and without knowledge of the COC used or 
any other of the participant’s characteristics. 
The ethinylestradiol dose was categorised into 20 µg, 30 µg, ≥35 µg per pill and triphasic prepa-
rations, which have a varying ethinylestradiol and progestagen doses over 21 days. The effect of 
progestagen and dose of ethinylestradiol on SHBG levels was assessed using linear regression 
analysis. The analysis was adjusted for study and to ensure that the effect of ethinylestradiol dose 
on SHBG levels is independent of the progestagen used, we adjusted this analysis for the pro-
gestagen used in COC. Regarding the effect of progestagen in COC on SHBG levels, the analysis 
was restricted to subjects taking 30 µg ethinylestradiol per contraceptive pill. To reduce random 
variation in SHBG levels, the analyses were adjusted forwhether women were menstruating at 
the time of venipuncture, and for age and BMI which can influence SHBG levels. Results were 
expressed as mean differences with 95% confidence interval.
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Overall, women were about 33 years (range: 18-49) and had a BMI of 23.3 kg/m2 (range: 15.7-
37.9). The mean SHBG plasma level was 139.5 nmol/L (95%CI: 131.2-147.8, IQR 99.8, range 28.0-
390.9). In the MEGA study, SHBG levels were compared between menstruating women versus 
women taking a pill at venipuncture. 11 women were menstruating at time of venipuncture and 
the mean SHBG level was 102.1 nmol/L (95%CI: 59.1-145.0) whereas the level in women who 
were taking a pill (N=163) was 145.4 nmol/L (95%CI: 134.3-156.6); mean difference: 43.4 nmol/L 
(95%CI: -1.0 -87.7). When we restricted our analysis to women receiving 30 µg of ethinylestradiol, 
users of desogestrel, gestodene, and drospirenone had approximately 100 nmol/L higher SHBG 
levels than users of levonorgestrel (Table). Adjustment for factors influencing SHBG levels did not 
change these results. After adjustment for progestagen, users of ≥35 µg of ethinylestradiol had 
higher SHBG levels than users of 20 µg (Table). Also users of triphasic contraceptives had higher 
SHBG levels than users of 20 µg of ethinylestradiol. The SHBG levels were only slightly higher 
in users of 30 µg compared with 20 µg of ethinylestradiol. Adjustment for factors influencing 
SHBG levels did not change these results. The same results were observed when the analysis 
of ethinylestradiol dose and SHBG levels was restricted to most commonly used progestagens 
(levonorgestrel, desogestrel and gestodene) or separately per these progestagens, although the 
number of women per category became very small. Furthermore, similar results were observed 
when the analysis was performed per study. Additional to the progestagens levonorgestrel, 
gestodene, desogestrel, and drospirenone, 30 women used cyproterone acetate. The mean SHBG 
level in users of cyproterone acetate was high at 215.9 nmol/L (95%CI: 199.7-232.1); much higher 
than in users of COC containing levonorgestrel with 30 µg ethinylestradiol (mean difference: 
135.4 nmol/L, (95%CI: 116.9-153.9) adjusted for study and menstruating at venipuncture).
One other paper evaluated the effect of different COC on SHBG levels and provided information on 
ethinylestradiol dose per progestagen (4). However, no direct comparisons between ethinylestra-
diol dose and SHBG levels were made; therefore, no conclusions could be drawn on whether 
the ethinylestradiol dose in different COC was reflected in SHBG levels. The positive association 
between ethinylestradiol dose and SHBG levels is in line with previous findings regarding venous 
thrombosis risk. Lidegaard et al. (5) reported that compared to users of oral contraceptive prepa-
rations containing 30-40 µg ethinylestradiol, the risk of venous thrombosis was higher in users 
of 50 µg ethinylestradiol (OR 1.6, 95%CI: 0.9-2.8) and lower in users of 20 µg (OR 0.6, 95%CI: 
0.4-0.9). In the MEGA study, we also demonstrated that within users of oral contraceptives con-
taining levonorgestrel, the risk of venous thrombosis was higher in users of 50 µg ethinylestradiol 
than in users of 30 µg (OR adjusted for age 2.2, 95%CI: 1.3-3.7) (6). The risk of venous thrombosis 
was lower in users of 20 µg than in users of 30 µg; both in users of progestagens gestodene (OR 
0.3, 95%CI: 0.2-0.7) and desogestrel (OR 0.7, 95%CI: 0.4-1.2).
Unfortunately, ethinylestradiol levels could not be measured directly because the blood was 
drawn at random during the four week cycle of pill use in the MEGA study and without consider-
ing the hours after a pill was taken, which both have a significant influence on ethinylestradiol 
levels (7). The hours after a pill was taken do not influence the SHBG levels, because of a half-life 
of SHBG of about 7 days. However, data were available on factors that were previously shown to 
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influence SHBG levels and on whether women were menstruating at venipuncture. Furthermore, 
regarding the analysis between ethinylestradiol dose and SHBG levels, we would have preferred 
to restrict our analysis to one progestagen; however, the number of women per category became 
very small leading to unreliable estimates. We combined two studies that differed in their design, 
which may have affected our results. However, the same results were observed in an analysis per 
study. Strengths of our study were that we included a relative large number of COC users who 
were using many different types of prescriptions. Furthermore, mean SHBG levels as well as the 
difference in SHBG levels between different progestagens in COC users were in the same range 
as observed in other studies.
In conclusion, SHBG levels reflect the ethinylestradiol dose used in COC independent of the 
progestagen used. Since ethinylestradiol is important in the pathogenesis of venous thrombosis 
in COC users, these findings strengthen the idea that SHBG levels in COC users may be seen as a 
marker for venous thrombosis risk.
Table: Mean SHBG levels and adjusted differences per progestagen or per ethinylestradiol dose
Mean SHBG levels * Adjusted difference * Adjusted difference †
Variable N (%) (95% CI) (95% CI) (95% CI)
Progestagen ‡
Levonorgestrel 99 (60) 80.3 (72.3 to 88.2) Reference Reference
Desogestrel 36 (22) 193.0 (179.9 to 206.2) 112.8 (97.3 to 128.2) 116.9 (101.1 to 132.7)
Gestodene 13 (8) 160.9 (138.8 to 183.0) 80.6 (57.3 to 104.0) 81.5 (56.3 to 106.6)
Drospirenone 17 (10) 191.3 (171.8 to 210.9 111.1 (89.8 to 132.3) 114.3 (93.1 to 135.5)
EE dose
20 µg 31 (11) 101.6 (80.4 to 122.8) Reference Reference
30 µg 165 (60) 115.3 (103.9 to 126.8) 13.8 (-7.1 to 34.6) 13.9 (-8.3 to 36.2)
≥35 µg 45 (16) 247.0 (200.6 to 293.4) 145.4 (87.1 to 203.7) 136.4 (64.5 to 208.3)
Triphasic 32 (12) 152.5 (132.7 to 172.4) 51.0 (22.8 to 79.1) 50.9 (20.7 to 81.1)
CI, confidence interval; EE, ethinylestradiol.
* Adjusted for progestagen in the case of ethinylestradiol dose and adjusted for study 
† Further adjusted for age, BMI and menstruating at venipuncture 
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The use of combined oral contraceptives is associated with a 3- to 6-fold increased risk of venous 
thrombosis. This increased risk depends on the estrogen dose as well as the progestogen type 
of combined oral contraceptives. Thrombin generation-based activated protein C resistance (APC 
resistance) and sex hormone-binding globulin (SHBG) levels predict the thrombotic risk of a com-
bined hormonal contraceptive. Recently, a four-phasic oral contraceptive containing dienogest 
(DNG) and estradiol valerate (E2V) has been marketed. The aim of this study was to evaluate the 
thrombotic risk of the DNG/E2V oral contraceptive by comparing APC resistance by measuring 
normalized APC sensitivity ratios (nAPCsr) and SHBG levels in users of oral contraceptives con-
taining dienogest and estradiol valerate (DNG/E2V) and oral contraceptives containing levonorg-
estrel and ethinyl estradiol (LNG/EE). Methods: We conducted a single-center, randomized, open 
label, parallel-group study in 74 women using DNG/E2V or LNG/ EE, and measured nAPCsr and 
SHBG levels in every phase of the regimen of DNG/E2V. 
Results
During the pill cycle SHBG levels did not differ between DNG/E2V users and LNG/EE users. nAPCsr 
levels were overall slightly lower in DNG/E2V users than in LNG/EE users, mean difference 0.44 
(95% CI, 1.04 to 0.17) for day 2, 0.20 (95% CI, 0.76 to 0.37) for day 7, 0.27 (95% CI, 0.81 to 0.28) for 
day 24 and 0.34 (95% CI, 0.91 to 0.24) for day 26.
Conclusion
No statistical significant differences in nAPCsr and SHBG levels were found between users of the 
oral contraceptive containing DNG/E2V and LNG/EE, suggesting a comparable thrombotic risk.
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Introduction
Use of combined oral contraceptives is associated with a 3- to 6-fold increased risk of venous 
thrombosis. This increased risk depends on the estrogen dose as well as the progestogen-type of 
combined oral contraceptives (1). Socalled ‘high-dose’ combined oral contraceptives containing 
50 µg or more ethinyl estradiol (EE) are associated with a 2-fold higher risk of thrombosis than 
‘low-dose’ combined oral contraceptives containing 20–30 µg EE (2;3). Furthermore, combined 
oral contraceptives containing the progestogens gestodene (GTD), desogestrel (DSG), cyproterone 
acetate (CPA) or drospirenone (DRSP) increase the risk of venous thrombosis by a factor two com-
pared with combined oral contraceptives containing levonorgestrel (LNG) (1–10).
The differences in the risk of venous thrombosis can at least partially be explained by the dif-
ferent effects of various combined oral contraceptives on the resistance to activated protein 
C (APC) as measured with the thrombin generation-based APC resistance test, and quantified 
via a normalized APC sensitivity ratio (nAPCsr) (11–13). High nAPCsr indicates increased APC 
resistance, which is a risk factor for venous thrombosis (14). The thrombin generation-based APC 
resistance test has been validated in a case–control study by Tans et al. (14) and discriminates 
well between oral contraceptives with a high risk of venous thrombosis (i.e. containing GTD, DSG, 
CPA or DRSP) and oral contraceptives with a lower risk of venous thrombosis (i.e. containing LNG) 
(3;6;9–13;15).
Sex hormone binding globuline (SHBG) is another marker that differentiates between combined 
oral contraceptives with a high and low risk of venous thrombosis (15–19). SHBG is a carrier 
protein, which is produced in the liver and binds estrogen and testosterone (20). Estrogens cause a 
dose-related increase of SHBG, whereas progestogens induce a decrease of SHBG, which depends 
on both the dose and type of progestogen (21;22). The effect of a hormonal contraceptive on 
SHBG is the net result of the estrogenic effect of estradiol and the antiestrogenic effect of the 
progestogen, yielding the total estrogenicity of that hormonal contraceptive. This estrogenicity 
serves as a marker for the thrombotic risk of a hormonal contraceptive (15–18).
Recently, a new, four-phasic, combined oral contraceptive containing dienogest and estradiol 
valerate (Qlaira; Bayer Schering Pharma, Berlin, Germany) was marketed. Dienogest (DNG) is a 
progestogen derived from the estrane structure and has antiandrogenic and no androgenic prop-
erties (23). Estradiol valerate (E2V) is an ester of the natural female hormone 17ß-estradiol. The 
risk of venous thrombosis of this new oral contraceptive containing DNG/E2V is unknown.
In order to estimate this thrombotic risk we conducted a randomized controlled trial in which we 
compared APC resistance and SHBG levels during use of the four-phasic oral contraceptive con-
taining DNG/E2V with a monophasic oral contraceptive containing LNG/EE. Our hypothesis was 
that the new oral contraceptive containing DNG/E2V has comparable levels of nAPCsr and SHBG 






Study design and participants
We conducted a single-center, randomized, open label, parallel-group study in Leiden, the 
Netherlands. Participants were recruited between May 2010 and January 2011 by advertis-
ing in local newspapers and in public and university buildings. The study was approved by the 
Medical Ethics Committee of the Leiden University Medical Center. The trial registration number 
is NTR2354. The study was sponsored by the Department of Clinical Epidemiology of the Leiden 
University Medical Center.
Eligible participants were women aged 18–35 years who were willing to use either one of the 
studied combined oral contraceptives. Exclusion criteria were contraindications for oral contra-
ceptive use as stated by the World Health Organization (24), pregnancy occurring up to 3 months 
before the study, use of anticoagulants or platelet aggregation inhibitors, and chronic or serious 
acute illness.
Participants were randomly assigned in a 1:1 ratio to either the four-phasic combined oral con-
traceptive containing DNG/E2V or the mono-phasic combined oral contraceptive containing LNG/
EE. The four-phasic DNG/E2V contraceptive pill contains no DNG and 3 mg E2V on days 1–2, 2 
mg DNG and 2 mg E2V on days 3–7, 3 mg DNG and 2 mg E2V on days 8–24, no DNG and 1 mg 
E2V on days 25–26 and a placebo on days 27–28 of the cycle. The mono-phasic LNG/EE contra-
ceptive pill contains 150 µg LNG and 30 µg EE on days 1–21 and was not taken on days 22–28. 
Participants used the contraceptives according the prescription for three consecutive cycles and 
all started on the first day of their menstrual cycle. After inclusion, women completed a standard-
ized questionnaire covering questions on risk factors for venous thrombosis.
Randomization was done by a computer-generated random allocation sequence. The treatment 
allocation sequence was concealed by sequentially numbered, opaque, sealed and stapled enve-
lopes. The envelopes were kept by an independent person at a central office, outside of the 
department and not involved in the study. After inclusion of a participant by the researcher, the 
first following numbered envelope was opened at the central office; on the card inside was 
described whether the patient was randomized to the LNG/EE group or the DNG/E2V group. This 
information was given to the researcher and participant, and was sent to the pharmacy to provide 
the medication. Researchers and allocated participants were aware of the allocated arm; labora-
tory technicians were kept blinded to the allocation. 
Eighty-eight participants were included (Fig. 1). Nine participants abandoned the trial before 
completion, of whom four participants discontinued because of side effects, two participants did 
not want to use an oral contraceptive anymore, two participants were lost to followup and one 
participant used the oral contraceptive incorrectly. All these participants abandoned the trial 
before the blood draws in the third cycle of use. Three participants turned out to be carriers of the 
factor V Leiden (FVL) mutation, and two participants were carriers of the prothrombin mutation 
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and were therefore excluded. The analysis was performed according to the per protocol principal, 
because we only want to use data during use of the contraceptive and missing data cannot be 
replaced. The number of participants who were lost to follow-up is balanced in both groups. In 
our final analysis, we used the data of 74 participants: 35 users (47%) of DNG/E2V and 39 users 
(53%) of LNG/EE.
Fig. 1. Flow diagram of exclusions.
Enrollment
Allocated to LNG/EE (n = 45)
Received allocated intervention (• n = 45)
Allocated to DNG/E2V (n = 43)
Received allocated intervention (• n = 43)
Allocation
Lost to follow-up (n = 2)
Discontinued due to side effects (• n = 2)
Lost to follow-up (n = 6)
Did not come to appointments (• n = 2)
Due to side effects (• n = 2)
Due to incorrect use (• n = 1)
Did not want to use OC anymore (• n = 2)
Follow-up
Excluded from analysis (n = 4):
Due to Factor V Leiden mutation (• n = 3)
Due to Prothrombin mutation (• n = 1)
Total excluded from analysis (n = 6)
Analyzed (n = 39)
Excluded from analysis (n = 1):
Due to Factor V Leiden mutation (• n = 0)
Due to Prothrombin mutation (• n = 1)
Total excluded from analysis (n = 8)
Analyzed (n = 35)
Analysis




The primary outcomes were APC resistance measured by the thrombin-generation-based APC 
resistance test resulting in normalized APC sensitivity ratios (nAPCsr) and SHBG levels during 
the third month of use. According to two studies of Wiegratz et al. , SHBG levels are stable after 
1 month of use (25;26). Blood samples were taken at inclusion and on days 2, 7, 24 and 26 in 
the third month of use. There was no wash out period. The blood samples were drawn from the 
antecubital vein in a fasting state in the morning and collected in 0.106 M sodium citrate (pH 5.8) 
and SST tubes (serum) (Becton, Dickinson and Company, Franklin Lakes, NJ, USA). Cell-free, citrated 
plasma was prepared by centrifuging blood at 2.100 g for 10 min at 18 °C, coded and centrally 
stored at 80 °C within 3 h after blood draw.
APC resistance was measured with the thrombin generation-based APC resistance test as 
described before (13).
SHBG (nM) was measured in serum with an immunometric assay (Immulite 2000 XPi; Siemens 
Healthcare Diagnostics, Tarrytown NY, USA). The sensitivity is 0.2 nM and has a long-term varia-
tion of 6% at both levels of 5 and 80 nM. The within-assay variation is 3–4% and the between-
assay variation 3.5 to 6%. 
After finishing the collection of blood samples the presence of the factor V Leiden mutation and 
the prothrombin G20210A mutation were measured in one run by DNA analysis. Carriers of a 
mutation were excluded.
Statistical analysis
Thirty-six participants had to be included in each group to detect a difference in nAPCsr of 0.52, 
which was previously observed between oral contraceptives containing levonorgestrel and des-
ogestrel (27) and considered relevant. We used a significance level of 0.05, a power of 80% and 
an anticipated dropout rate of 10%. 
We used means, mean differences, 95% confidence intervals and ranges to describe variables. We 
calculated P-values by performing t-tests and chi-squared tests to evaluate whether baseline 
characteristics were well balanced between the groups. A multivariate analysis was performed 
to investigate whether baseline characteristics had an influence on the outcomes. We performed 
t-tests to calculate mean differences of nAPCsr and SHBG levels between users of DNG/E2V and 
users of LNG/EE, separately calculated for the different phases of DNG/ E2V. We constructed bar 
diagrams to compute the figures. No interim analyses were performed. Statistics were computed 
using SPSS for Windows, version 20.0 (SPSS Inc., Chicago, IL, USA).
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Results
There were no differences in BMI, age and smoking habits between DNG/E2V users and LNG/
EE users, as shown in Table 1. There were no participants with thrombophilia, diabetes mellitus, 
history of venous thrombosis or other cardiovascular diseases and no participants used drugs on 
a regular basis (data not shown). A multivariate analysis including the variables age, BMI, smoking 
habit and family history shows that the outcome cannot be explained by differences in these 
variables (data not shown).
Over 93% of all participants used an oral contraceptive at the time of inclusion. Almost 80% of 
these oral contraceptives were second-generation pills containing LNG. No participants used an 
intrauterine device (IUD) or vaginally or transdermally administered contraceptives before inclu-
sion. One participant used a hormonal implant before inclusion, which was removed before start 
of participation.
Table 1: Baseline characteristics 
LNG/EE DNG/E2V P-value
N (%) 39 (53) 35 (47) -
Age, years (range) 22.7 (19–31) 21.9 (18–32) 0.43
BMI, kg/m2 (range) 22.1 (18–30) 22.3 (19–28) 0.59
Smoking (%) 0.76
    Non-customer 33 (84.6) 28 (80.0)
    Current 4 (10.3) 4 (11.4)
    Past 2 (5.1) 3 (8.6)
Contraceptive before study, n (%) 0.31
    None 2 (5.1) 2 (5.7)
    Oral contraceptive 36 (92.3) 33 (94.3)
        2nd generation 32 (82) 23 (65.7)
        3rd generation 1 (2.6) 0
    DRSP 1 (2.6) 4 (11.4)
    CPA 0 3 (8.6)
    DNG 0 1 (2.9)
    Unknown 2 (5.1) 2 (5.7)
    Implant 1 (2.6) 0
    IUD 0 0




Family history of venous  
thrombosis, first degree, n (%)
2 (5.1) 2 (5.1) 0.62
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SHBG levels and nAPCsr in DNG/E2V users and in LNG/EE users
During the pill cycle SHBG levels did not differ between DNG/E2V users and LNG/EE users, as 
shown in Table 2 and Fig. 3.
nAPCsr levels were overall lower in DNG/E2V users than in LNG/EE users, mean difference 0.44 
(95% CI, 1.04 to 0.17) for day 2, 0.20 (95% CI, 0.76 to 0.37) for day 7, 0.27 (95% CI, 0.81 to 0.28) for 
day 24 and 0.34 (95% CI, 0.91 to 0.24) for day 26 (Table 2 and Fig. 2).
SHBG levels and nAPCsr within the cycle
The nAPCsr did not differ during the pill cycle in users of LNG/EE and DNG/E2V (Fig. 2). 
In DNG/E2V users as well as in LNG/EE users SHBG levels were lower at the beginning of the pill 
cycle than at the end of the pill cycle (Fig. 3).
For LNG/EE users, the mean difference in SHBG was 7.10 nM (95% CI, 4.79 to 18.97) between days 
2 and 7, 23.53 nM (95% CI, 10.41 to 36.65) between days 7 and 24 and 1.51 nM (95% CI, 11.78 to 
14.81) between days 24 and 26.
For DNG/E2V users, the same pattern was observed: the mean difference in SHBG was 7.91 nM 
(95% CI, 3.48 to 19.30) between days 2 and 7, 33.44 nM (95% CI, 18.57 to 48.31) between days 7 
and 24 and 2.79 nM (95% CI, 13.00 to 18.59) between days 24 and 26.
Overall, the mean difference in SHBG between days 2 and 26 was 32.14 nM (95% CI, 20.10 to 
44.20) for LNG/ EE users, and 44.15 nM (95% CI, 31.57 to 56.72) for DNG/E2V users.
 
Table 2: Means, mean differences and confidence intervals of SHBG levels and nAPCsr at different phases 
in DNG/E2V compared with LNG/EE
SHGB (nM) nAPCsr
Phase Pill Contents Mean MD 95% CI Mean MD 95% CI
Phase 1, day 2 LNG/EE EE 30 μg, LNG 150 μg, 50.87 Ref –11.47 to 10.39 3.26 Ref 1.04 to 0.17
DNG/E2V E2V 3 mg 50.33 –0.54 2.83 –0.44
Phase 2, day 7 LNG/EE EE 30 μg, LNG 150 μg 57.96 Ref –12.37 to 12.94 3.30 Ref 0.76 to 0.37
DNG/E2V E2V 2 mg, DNG 2 mg 58.24 –0.28 3.11 –0.20
Phase 3, day 24 LNG/EE Pill-free interval 81.49 Ref –5.15 to 25.53 3.23 Ref 0.81 to 0.28
DNG/E2V E2V 2 mg, DNG 3 mg 91.68 10.19 2.97 –0.27
Phase 4, day 26 LNG/EE Pill-free interval 83.00 Ref –2.31 to 25 3.21 Ref 0.91 to 0.24
DNG/E2V E2V 1 mg 94.47 11.47 2.88 –0.34
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Fig. 2. Mean nAPCsr levels (ratio) and 95% confi dence intervals during use of LNG/EE and DNG/E2V, 
subdivided by cycle day.
Fig. 3. Mean SHBG levels (nM/L) and 95% confi dence intervals during use of LNG/EE and DNG/E2V, 




























In this randomized controlled trial on the effects of a four-phasic oral contraceptive containing 
DNG/E2V and a mono-phasic oral contraceptive containing LNG/EE on APC resistance and SHBG, 
we observed no significant differences between the two oral contraceptives. During the cycle, 
SHBG levels increased gradually in both DNG/ E2V users and in LNG/EE users. No difference in 
APC resistance was observed during the cycle.
The thrombin generation-based APC resistance test used in this study predicts the risk of venous 
thrombosis and discriminates well between oral contraceptives with a high and low thrombotic 
risk (14). SHBG is a marker that differentiates between combined oral contraceptives with a high 
and low risk of venous thrombosis (15–19). In our study we did not observe a difference in APC 
resistance and SHBG levels between a new oral contraceptive containing DNG/E2V and a low-risk 
combined oral contraceptive containing LNG/EE. These findings suggest that DNG/E2V and LNG/
EE have a comparable thrombotic effect and risk of venous thrombosis. However, clinical studies 
assessing the absolute and relative risk of venous thrombosis in women using DNG/E2V are indi-
cated to confirm this.
Our study is the first clinical, independent trial in which a group with representative sample size 
was randomized between LNG/EE and DNG/E2V. Two studies sponsored by the manufacturer that 
were published during the preparation of our manuscript show lower nAPCsr and SHBG levels for 
DNG/E2V compared with LNG/EE. Klipping et al. (28) conducted a randomized, open label, cross-
over study of DNG/E2V and monophasic LNG/EE and observed lower nAPCsr and lower SHBG 
levels in 25 users of DNG/E2V than in 25 users of LNG/EE. Junge et al. (29) performed a random-
ized, open label study and also observed less pronounced SHBG levels in 30 users of DNG/E2V 
than in 28 users of triphasic LNG/EE. In our study, nAPCsr levels were overall lower in users of 
DNG/E2V, but the differences were not statistically significant. Based on the results of these three 
studies, it can be stated that DNG/E2V does not lead to a more thrombogenic state compared 
with LNG/EE.
E2V seems to have a favorable effect on thrombotic markers compared with EE. The oral 
contraceptive used in our study containing DNG/E2V is the first marketed combined oral contra-
ceptive containing E2V. Before, most combined oral contraceptives contained EE as an estrogen 
compound. In a study by Wiegratz et al. (25) users of oral contraceptives containing 2 mg DNG and 
20 µg EE had higher SHBG levels than users of oral contraceptives containing 100 µg LNG and 20 µg 
EE. In our study no differences in SHBG were observed between users of DNG/E2V and LNG/EE. 
No studies that assessed the effect of DNG/EE on nAPCsr have been conducted and no studies 
assessing the risk of venous thrombosis due to combined oral contraceptives containing E2V as 
estrogen content have been performed. 
During the cycle, increasing SHBG levels were observed, even in the pill-free interval of users of 
LNG/ EE. This is in agreement with other studies. Devineni et al. (30) observed increasing SHBG 
levels during the cycle in users of the contraceptive patch containing norelgestromin and EE, and 
users of the combined oral contraceptive containing norgestimate and EE. Wiegratz et al. (25) 
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observed increasing SHBG levels throughout the cycle during use of four different combined oral 
contraceptives. As the biological half-life of SHBG is supposed to be around 2–4 days, this can be 
explained by decreasing levels of SHBG, which do not reach baseline levels during the pill-free 
interval. This indicates that the cyclic variability of SHBG during use of oral contraceptives should 
be taken into account in future studies; SHBG should be measured at the same moment in the 
cycle to prevent bias caused by increasing SHBG levels throughout the cycle.
Some potential limitations need to be addressed. Caution is required when surrogate markers 
are used, as they can be severely misleading (31). Preferably, a surrogate marker is validated in 
a prospective trial. nAPCsr is a validated surrogate marker; SHBG is not validated yet, but is a 
recommended measurement before marketing of a new hormonal contraceptive by the European 
Medicines Agency (EMA). In the case of very rare events, such as venous thrombosis during com-
bined hormonal contraceptive use, a clinical study is almost unfeasible before marketing, due to 
the required number of participants (24;32).
Remarkably, no increasing nAPCsr levels were observed throughout the cycle and there was no 
correlation found between SHBG levels and nAPCsr levels (data not shown). In previous studies, 
a correlation between SHBG and nAPCsr was observed in users of hormonal contraceptives 
(15;19). This might be explained by the sample size of our study, which is probably too small to 
demonstrate a correlation.
In conclusion, we found similar SHBG levels and APC resistance in users of DNG/E2V and LNG/EE- 
containing oral contraceptives, which suggests a similar thrombotic risk for both oral contracep-
tives. Since oral contraceptives containing DNG/EE causes a stronger rise in SHBG levels, the 
similar effects found in this study might be explained by a favorable effect of E2V compared with 
EE. Future studies are indicated to assess whether E2V and EE have different effects on hemo-
static and other parameters and on the risk of venous thrombosis. Epidemiological studies are 
needed to confirm the hypothesis that DNG/E2V and LNG/EE are equally safe regarding the risk 




1  Vandenbroucke JP, Rosing J, Bloemenkamp KWM, Middeldorp S, Helmerhorst FM, Bouma BN, 
Rosendaal FR. Oral contraceptives and the risk of venous thrombosis. N Engl J Med 2001; 344: 
1527–34.
2   Rosendaal FR, van Hylckama Vlieg A, Tanis BC, Helmerhorst FM. Estrogens, progestogens and 
thrombosis. J Thromb Haemost 2003; 1: 1371–80.
3   van Hylckama Vlieg A, Helmerhorst FM, Vandenbroucke JP, Doggen CJ, Rosendaal FR. The 
venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: 
results of the MEGA case–control study. BMJ 2009; 339: b2921.
4   Bloemenkamp KW, Rosendaal FR, Helmerhorst FM, Buller HR, Vandenbroucke JP. Enhancement 
by factor V Leiden mutation of risk of deep vein thrombosis associated with oral contraceptives 
containing a third-generation progestagen. Lancet 1995; 346: 1593–6.
5   Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic 
disease. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid 
Hormone Contraception. Lancet 1995; 346: 1582–8.
6   Lidegaard O, Lokkegaard E, Svendsen AL, Agger C. Hormonal contraception and risk of venous 
thromboembolism: national follow-up study. BMJ 2009; 339: b2890.
7   Jick H, Jick SS, Gurewich V, Myers MW, Vasilakis C. Risk of idiopathic cardiovascular death and 
nonfatal venous thromboembolism in women using oral contraceptives with differing progesta-
gen components. Lancet 1995; 346: 1589–93.
8   van Hylckama Vlieg A, Middeldorp S. Hormone therapies and venous thromboembolism: where 
are we now? J Thromb Haemost 2011; 9: 257–66.
9   Jick SS, Hernandez RK. Risk of non-fatal venous thromboembolism in women using oral contra-
ceptives containing drospirenone compared with women using oral contraceptives containing 
levonorgestrel: case–control study using United States claims data. BMJ 2011; 342: d2151.
10   Parkin L, Sharples K, Hernandez RK, Jick SS. Risk of venous thromboembolism in users of oral 
contraceptives containing drospirenone or levonorgestrel: nested case–control study based on 
UK General Practice Research Database. BMJ 2011; 342: d2139.
11   Rosing J, Middeldorp S, Curvers J, Christella M, Thomassen LG, Nicolaes GA, Meijers JC, Bouma 
BN, Buller HR, Prins MH, Tans G. Low-dose oral contraceptives and acquired resistance to acti-
vated protein C: a randomised cross-over study. Lancet 1999; 354: 2036–40.
12   van Vliet HA, Winkel TA, Noort I, Rosing J, Rosendaal FR. Prothrombotic changes in users 
of combined oral contraceptives containing drospirenone and cyproterone acetate. J Thromb 
Haemost 2004; 2: 2060–2.
13   Tchaikovski SN, van Vliet HA, Thomassen MC, Bertina RM, Rosendaal FR, Sandset PM,  
Helmerhorst FM, Tans G, Rosing J. Effect of oral contraceptives on thrombin generation mea-
sured via calibrated automated thrombography. Thromb Haemost 2007; 98: 1350–6.
14   Tans G, van Hylckama Vlieg A, Thomassen MC, Curvers J, Bertina RM, Rosing J, Rosendaal FR. 
Activated protein C resistance determined with a thrombin generation-based test predicts for 
venous thrombosis in men and women. Br J Haematol 2003; 122: 465–70.
15   Raps M, Helmerhorst F, Fleischer K, Thomassen S, Rosendaal F, Rosing J, Ballieux B, van Vliet H. 
Sex hormone-binding globulin as a marker for the thrombotic risk of hormonal contraceptives. J 
Thromb Haemost 2012; 10: 992–7.
16   Stegeman BH, Raps M, Helmerhorst FM, Vos HL, van Vliet HA, Rosendaal FR, van Hylckama 
Vlieg Al. Effect of ethinylestradiol dose and progestagen in combined oral contraceptives on 
plasma sex hormone binding globulin levels in premenopausal women. J Thromb Haemost 2013; 
11: 203–5.
97
Resistance to APC and SHBG levels during use of a four-phasic oral contraceptive containing 
dienogest and estradiol valerate: a randomized controlled trial
17   Odlind V, Milsom I, Persson I, Victor A. Can changes in sex hormone binding globulin predict the 
risk of venous thromboembolism with combined oral contraceptive pills? Acta Obstet Gynecol 
Scand 2002; 81: 482–90.
18   van Vliet HA, Rosendaal FR, Rosing J, Helmerhorst FM. Sex hormone-binding globulin: an 
adequate surrigate marker for venous thromboembolism in women using new hormonal contra-
ceptives. Contraception 2009; 79: 328–30.
19   van Vliet HA, Frolich M, Christella M, Thomassen LG, Doggen CJ, Rosendaal FR, Rosing J, Hel-
merhorst FM. Association between sex hormone-binding globulin levels and activated protein C 
resistance in explaining the risk of thrombosis in users of oral contraceptives containing differ-
ent progestogens. Hum Reprod 2005; 20: 563–8.
20   Gardner DG. Greenspan’s Basic & Clinical Endocrinology, 8th edn. New York: McGraw-Hill Com-
panies Inc., 2007.
21   van der Vange N, Blankenstein MA, Kloosterboer HJ, Haspels AA, Thijssen JH. Effects of seven 
low-dose combined oral contraceptives on sex hormone binding globulin, corticosteroid binding 
globulin, total and free testosterone. Contraception 1990; 41: 345–52.
22   Knopp RH, Broyles FE, Cheung M, Moore K, Marcovina S, Chandler WL. Comparison of the 
lipoprotein, carbohydrate, and hemostatic effects of phasic oral contraceptives containing des-
ogestrel or levonorgestrel. Contraception 2001; 63: 1–11.
23   Sitruk-Ware R, Mishell DR. Progestins and Antiprogestins in Clinical Practice. New York: Marcel 
Dekker Inc., 2000.
24   WHO. Medical eligibility criteria for contraceptive use. 4th edn, Geneva: WHO, 2009. Available 
at http://www.who.int/reproductivehealth/publications/family_planning/9789241563888/en/
index.html
25   Wiegratz I, Kutschera E, Lee JH, Moore C, Mellinger U, Winkler UH, Kuhl H. Effect of four differ-
ent oral contraceptives on various sex hormones and serum-binding globulins. Contraception 
2003; 67: 25–32.
26   Wiegratz I, Jung-Hoffmann C, Kuhl H. Effect of two oral contraceptives containing ethinylestra-
diol and gestodene or norgestimate upon androgen parameters and serum binding proteins. 
Contraception 1995; 51: 341–6.
27   Tans G, Curvers J, Middeldorp S, Thomassen MC, Meijers JC, Prins MH, Bouma BN, B€uller HR, 
Rosing J. A randomized cross-over study on the effects of levonorgestrel- and desogestrelcon-
taining oral contraceptives on the anticoagulant pathways. Thromb Haemost 2000; 84: 15–21.
28   Klipping C, Duijkers I, Parke S, Mellinger U, Serrani M, Junge W. Hemostatic effects of a novel 
estradiol-based oral contraceptive: an open-label, randomized, crossover study of estradiol val-
erate/ dienogest versus ethinylestradiol/levonorgestrel. Drugs R D. 2011; 11: 159–70.
29   Junge W, Mellinger U, Parke S, Serrani M. Metabolic and haemostatic effects of estradiol valer-
ate/dienogest, a novel oral contraceptive: a randomized, open-label, single-centre study. Clin 
Drug Investig 2011; 31: 573–84.
30   Devineni D, Skee D, Vaccaro N, Massarella J, Janssens L, La-Guardia KD, Leung AT. Pharmacoki-
netics and pharmacodynamics of a transdermal contraceptive patch and an oral contraceptive. J 
Clin Pharmacol 2007; 47: 497–509.
31   Stanczyk FZ, Grimes DA. Sex hormone-binding globulin: not a surrogate marker for venous 
thromboembolism in women using oral contraceptives. Contraception 2008; 78: 201–3. 32 Car-
diovascular disease and steroid hormone contraception. Report of a WHO Scientific Group. World 
Health Organ Tech Rep Ser 1998; 877: 1–89.

CHAPTER 7
Thyroid function, activated protein C 
resistance and the risk of venous 









Huib A.A.M. van Vliet





Use of combined hormonal contraceptives is associated with a three- to eight-fold increased risk 
of venous thrombosis compared with non-use. The thrombotic risk depends on the estrogen dose 
as well as the progestogen type. Use of hormonal contraceptives leads to resistance to activated 
protein C (APC), which may serve as marker for the risk of venous thrombosis. Hyperthyroidism 
is also associated with an increased risk of venous thrombosis, due to increased free Thyroxine 
(FT4) levels which cause a hypercoagulable state. 
Materials and methods
The objective of this study was to evaluate the effects of hormonal contraceptives on levels of 
FT4, thyroid stimulating hormone (TSH) and thyroxine binding globulin (TBG), and to investigate 
the effects on APC resistance per contraceptive group. We measured FT4, TBG and TSH levels and 
APC resistance in 231 users of oral contraceptives. 
Results
Users of the most thrombogenic hormonal contraceptives, i.e. containing desogestrel, cyproterone 
acetate or drospirenone, had higher TBG levels than users of less thrombogenic hormonal contra-
ceptives , i.e. the levonorgestrel-containing intrauterine device. TSH levels were not significantly 
elevated and FT4 levels did not change. TBG levels were also associated with APC resistance. 
Conclusion 
Use of hormonal contraceptives lead to elevated TBG levels, slightly elevated TSH levels and 
unchanged FT4 levels without causing a hyperthyroid state. Thus, the increased thrombotic risk 
during the use of hormonal contraceptives cannot be explained by a hyperthyroid state caused 
by use of these hormonal contraceptives.
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Introduction
Use of combined hormonal contraceptives is associated with a three- to eight-fold increased risk 
of venous thrombosis (1-3). The risk depends on the estrogen dose as well as the progestogen 
type (1). So-called ‘high-dose’ combined oral contraceptives containing 50 µg or more ethi-
nylestradiol (EE) are associated with a two-fold higher risk of venous thrombosis than ‘low-dose’ 
combined oral contraceptives containing 20 to 30 µg EE (2;4). Combined oral contraceptives 
containing the progestogens gestodene (GTD), desogestrel (DSG), cyproterone acetate (CPA) 
or drospirenone (DRSP) increase the risk of venous thrombosis two-fold more than combined 
oral contraceptives containing levonorgestrel (LNG) (1;2;4-13). The contraceptive vaginal ring 
containing etonogestrel (ENG) and EE, and use of the contraceptive transdermal patch containing 
norelgestromin (NGMN) and EE, are both associated with a seven- to eight-fold increased risk 
of venous thrombosis compared with non-users (14). Use of an intrauterine device (IUD), either 
levonorgestrel-releasing or without hormones, is not associated with an increased risk of venous 
thrombosis (15). 
The differences in the risk of venous thrombosis can at least be partially explained by the different 
effects of various combined oral contraceptives on the resistance to activated protein C (APC) as 
measured with the thrombin generation-based APC resistance test, and quantified via a normal-
ized APC sensitivity ratio (nAPCsr) (16-18). High nAPCsr indicates increased APC resistance, which 
is dose-dependently associated with venous thrombosis (19). The thrombin generation-based 
APC resistance test was validated in a case-control study by Tans et al. (19) and discriminated well 
between highly thrombogenic oral contraceptives (i.e., containing GTD, DSG, CPA or DRSP) and 
oral contraceptives with a lower risk of venous thrombosis (i.e., containing LNG) (2;7;10;18).
Oral contraceptives influence the blood plasma concentrations of several binding globulins pro-
duced by the liver. The concentrations of these binding globulins are dependent on the effect of 
EE which enhances hepatic globulin synthesis (20-25), and the effect of the progestogen com-
pound which degrades hepatic globulin syntheses. This results in an overall effect known as 
“estrogenicity”. For example, use of combined hormonal contraceptives increases levels of sex 
hormone binding globulin (SHBG), which is the resultant of a dose-related increase induced by 
estrogens and a type- and dose-related decrease induced by progestogens (20;26). SHBG levels 
are associated with nAPCsr and the risk of venous thrombosis during use of hormonal contra-
ceptives (27;28) and therefore serve as surrogate marker for the thrombogenicity of a hormonal 
contraceptive. SHBG measurement is recommended for estimation of the thrombotic risk before 
a new hormonal contraceptive is marketed (29).
Hyperthyroidism is associated with an increased risk of venous thrombosis (30-34) and causes a 
hypercoagulable state. This is due to high free thyroxine (T4) levels which influence the coagu-
lation system (30-32). During use of hormonal contraceptives thyroxine binding globulin (TBG) 
levels are increased (20-26). TBG is, as SHBG, a hepatic globulin, which in this case transports 




We conducted an observational study to assess the effects of various hormonal contraceptives 
with various routes of administration and different thrombotic risks on TBG, TSH and FT4 levels 
as parameters of thyroid function. In addition, we evaluated whether TBG, TSH and FT4 levels are 
associated with the nAPCsr as marker of venous thrombosis, and with the thrombogenicity of a 
contraceptive as reported in the literature. 
Materials and Methods
Study design and participants
We conducted an observational study. Plasma samples of participants from three different, previ-
ously performed studies collected between July 2002 and December 2005 in Leiden, the Nether-
lands, were used for analysis (17;35-37). Participants of two observational studies on the use of 
the levonorgestrel containing IUD (LNG-IUD) and copper containing IUD (Cu-IUD) and on the use 
of different combined oral contraceptives on markers of venous thrombosis were included. The 
third study was a randomized controlled trial with cross-over design on the effect of the vaginal 
ring and transdermal patch compared with the LNG and EE containing combined oral contracep-
tive on markers for venous thrombosis. All participants used their contraceptive for at least three 
consecutive months; blood draws were performed at baseline and in the third month of use. A 
more detailed description can be found in the original articles (17;35-37).
Inclusion criteria of all participants were: healthy women using a hormonal contraceptive for 
at least three cycles. Exclusion criteria were age <18 years, and contraindications for combined 
hormonal contraceptive use as stated by the World Health Organization (3). No participants had 
a history of thyroid disease, or used medication for a thyroid disorder. 
Participants who were carriers of the factor V Leiden mutation were excluded from the analy-
sis, since this mutation causes resistance to APC without affecting levels of TBG, FT4 and TSH 
(n = 36). Users of contraceptives with less than 10 users were not included in the final analysis: 
users of the combined oral contraceptives containing GTD (n = 3), norgestimate (NGM, n = 1) and 
norethisterone (NET, n = 2), users of the transdermal patch containing NGMN and EE (n = 7) and 
users of the vaginal ring containing ENG and EE (n = 5). To exclude effects of the estrogen dose, 
we only used data from users of combined oral contraceptives containing 30-35 µg of EE; users 
of preparations with other amounts of EE were excluded (n = 23). 
The final analysis included 231 participants: 154 users of a combined oral contraceptive (con-
taining 30-35µg EE and LNG, DSG, CPA or DRSP), 60 users of the LNG-IUD and 17 users of the 
Cu-IUD.
Written informed consent was given by all participants and the studies were all approved by the 
Medical Ethics Committee of the Leiden University Medical Center, The Netherlands.
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Laboratory methods
The plasma samples from the studies were taken, processed and stored identically. Blood samples 
were taken from the antecubital vein in the morning in a fasting state and collected in 0.106 M 
sodium citrate (pH 5.8), and in tubes with a clotting activator to obtain serum. Cell-free, citrated 
plasma and serum were prepared by centrifuging blood at 2100 g for 10 minutes at 18ºC, and 
were coded and centrally stored at -80 ºC. All samples were measured in a single run, using one 
lot of reagents by technicians who were unaware of which participant or contraceptive a sample 
belonged to.
Normalized APC sensitivity ratios (nAPCsr) were determined in duplicate by quantifying the 
effect of APC on thrombin generation in the thrombin generation-based APC resistance test, as 
described before (16). 
TBG (nmol/L) was measured with a competitive chemiluminescent immunoassay (Immulite 2000; 
Siemens, USA). Sensitivity of the assay is 29 nmol/L with an imprecision of 7%. Values between 
330 and 760 nmol/L are considered within reference range.
TSH (mIU/L) was measured with a chemiluminescent sandwich ELISA and FT4 (pmol/L) was mea-
sured with a competitive chemiluminescent assay (Roche Cobas 6000, E-platform, Switzerland). 
Imprecision of the TSH assay is 1.3%, with a sensitivity of 0.01 mIU/L. Reference values applied 
at the institution are 0.27 to 4.2 mIU/L for adults. The FT4 assay has an imprecision of 3% and a 
sensitivity of 0.3 pmol/L. The institution uses a 10 to 24 pmol/L reference range for adults.
Statistical analysis
We used means, mean differences (MD), 95% confidence intervals (95% CI) and ranges to describe 
variables. We performed a normality analysis, constructed error bars and a scatter plot to describe 
the association between TBG levels and nAPCsr, and performed a regression analysis to study 
associations. Statistics were computed using SPSS for Windows, version 20.0 (SPSS Inc., Chicago, 
IL, USA). The odds ratios of the risk of venous thrombosis during use of different hormonal con-
traceptives were retrieved from recent publications of Van Hylckama Vlieg et al. (2;15) and were 
used for risk ranking. Users of the Cu-IUD were considered as non-users since the Cu-IUD does 
not contain hormones and does not increase the risk of venous thrombosis.
Results
Baseline characteristics
There were no statistically significant differences in age or body mass index (BMI) between the 
women using different kinds of hormonal contraceptives. The mean age of the total group was 29 
years (range 17 to 52 years), the mean BMI was 24 kg/m2 (range 17 to 48 kg/m2) (Table 1). None of 
the participants used levothyroxine or reported a thyroid disorder. A more detailed description of 
the characteristics of the participants can be found in previous papers (17;35;36).
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TBG, TSH and FT4 levels during use of hormonal contraceptives
The lowest TBG levels were found in women using the LNG-IUD with a mean of 331 nmol/L, 
compared with a mean TBG level of 366 nmol/L during use of the Cu-IUD (MD -35 nmol/L, 95% CI 
-71 to 0). Users of the oral contraceptives containing DSG and EE had the highest TBG levels with 
a mean of 629 nmol/L (MD 247 nmol/L, 95% CI 183 to 312) (Table 2).
TSH levels were also increased during use of hormonal contraceptives: the lowest levels were 
found in users of the Cu-IUD 2.13 mIU/L, users of the DRSP/EE containing oral contraceptive had 
the highest TSH level of 3.01 mIU/L. (Table 2). 
FT4 levels were not significantly different during use of hormonal contraceptives compared with 
use of the Cu-IUD (Table 2). 
Associations
TBG plasma levels were positively associated with nAPCsr in users of different kinds of hormonal 
contraceptives. TBG levels increased by 17% for each one-unit increase in nAPCsr (10^0.068 = 
1.17), equation: log10 (TBG) = 2.494 + (nAPCsr * 0.068) (Figure 1). The Pearson’s correlation coef-
ficient was 0.714 (p<0.001).
Risk ranking per contraceptive
For risk ranking, we used odds ratios from recent publications of Van Hylckama Vlieg et al. (2;15). 
The TBG levels were associated with the reported thrombogenicity of oral contraceptives: users 
of highly thrombogenic contraceptives had higher TBG levels than users of oral contraceptives 
with a low thrombogenicity (Table 2).
Table 1: Baseline characteristics
Contraceptive N Age, years (range) p value BMI, kg/m2 (range) p value
LNG-IUD 60 33 (17–52) 0.84 25 (18–48) 0.64
Cu-IUD 17 30 (20–45) Ref 24 [18–32] Ref
LNG/EE 71 29 (19–51) 0.09 23 [17–38] 0.35
DSG/EE 16 31 (18–49) 0.51 25 [20–32] 0.59
DRSP/EE 46 29 (18–47) 0.08 24 [18–34] 0.85
CPA/EE 21 28 (19–44) 0.07 22 [19–26] 0.15
BMI, body mass index; IUD, intrauterine device; LNG, levonorgestrel; Cu, copper; EE, ethinylestra-
diol; DSG, desogestrel; DRSP, drospirenone; CPA, cyproterone acetate.
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Discussion
In this study of 231 users of various hormonal contraceptives with different routes of administra-
tion we observed different levels of TBG, TSH and FT4. TBG levels were positively associated with 
the thrombotic marker nAPCsr. Users of hormonal contraceptives with a known high thrombo-
genicity had the highest TBG levels, and users of the LNG-IUD, which is not associated with an 
increased risk of venous thrombosis, had the lowest TBG levels. TSH levels displayed a similar but 
less pronounced pattern. 
Several studies have reported increases in TBG levels during use of combined oral contraceptives. 
Wiegratz et al. (20) published a randomized controlled trial with four different oral contraceptives. 
All four preparations led to increased serum levels of TBG, and a less pronounced rise of total T4 
and T3 which was most likely the result of the increased TBG levels. They explain the elevation of 
TBG by an EE-induced enhancement of the hepatic TBG synthesis and a counteraction by proges-
togens as illustrated by the difference in users of oral contraceptives containing LNG compared 
with DNG (20). Ågren et al. (23) and Sänger et al. (21) also observed increased TBG levels in women 
using different combined oral contraceptives. In these two studies TSH and FT4 levels were only 
minimally affected. We also did not observe a difference in FT4 between users of hormonal contra-
ceptives and users of the non-hormonal Cu-IUD. For TSH, a trend similar to TBG was observed: 
highly thrombogenic hormonal contraceptives were associated with higher TSH levels than less 
thrombogenic hormonal contraceptive, indicating that the pituitary-hypothalamic axis was affected 
to some extent. Our findings confirm the data of Ågren, Sänger and Wiegratz (21;23;38).
Limited data are available about the vaginal ring containing ENG and the transdermal patch 
containing NGMN. Duijkers et al. investigated the effect of the vaginal ring on TSH and FT4 
(25). They observed comparable FT4 levels, and higher TSH levels for users of the vaginal ring 
than for to users of an oral contraceptive containing LNG and EE. No TBG levels were reported. 
White et al. (24)  investigated the effect of the transdermal patch on TBG levels, compared with an 
oral contraceptive containing NGM and EE. They found higher TBG levels in users of the transder-
mal patch than for the oral contraceptive. We excluded users of the vaginal ring and transdermal 
patch due to a small sample size (n = 5 for the vaginal ring and n = 7 for the transdermal patch). 
Use of hormonal contraceptives and hyperthyroidism are both associated with an increased risk 
of venous thrombosis (1-4;6;7;13;14;30-34). Use of hormonal contraceptives causes resistance to 
APC, and changes of the plasma levels of several procoagulant, anticoagulant and fibrinolytic pro-
teins (39-43). Hyperthyroidism increases antifibrinolysis and induce changes in the inflammatory 
pathway through complement C3 which induces a hypercoagulable state (34;39). We observed 
that use of hormonal contraceptives influence thyroid parameters but does not lead to a hyper-
thyroid state since FT4 levels were not much affected. So, the increased risk of venous thrombosis 
during use of hormonal contraceptives cannot be explained by a hyperthyroid state induced by 
hormonal contraceptives which causes hypercoagulability. Like other hepatic binding globulins 
such as SHBG, TBG levels are associated with the increased risk of venous thrombosis during use 
of hormonal contraceptives (26;28;44).
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Currently, a biological explanation of the increased risk of venous thrombosis during use of com-
bined hormonal contraceptives is lacking. It seems likely that the liver plays a modulating role 
in the increased risk of venous thrombosis during use of combined hormonal contraceptives: 
the serum levels of hepatic binding globulins are increased during use of combined hormonal 
contraceptives, coagulation factors are produced in the liver and hormonal contraceptives are 
metabolized in the liver. Possibly, combined hormonal contraceptives interfere with the synthesis 
of both binding globulins and coagulation factors. 
Limitations of our study were the sample size of some contraceptive groups and the reference 
group. The sample sizes of users of various contraceptives were too small for comparison and 
had to be excluded from the analysis, including the non-oral contraceptives vaginal ring and 
transdermal patch. Besides, non-users are preferably used as reference group. However, data of 
non-users were not available and therefore users of the Cu-IUD served as reference group since 
use of the Cu-IUD is not thought to increase the risk of venous thrombosis and considered inert. 
In conclusion, this study shows that the use of hormonal contraceptives leads to increased TBG 
levels and TSH levels, but has no effect on FT4 levels during use of hormonal contraceptives. 
Hormonal contraceptive use does not lead to a hyperthyroid state, and hence the increased risk 
of venous thrombosis during use of combined hormonal contraceptives cannot be explained by 
a hyperthyroid state induced by hormonal contraceptives which causes hypercoagulability. TBG 
reflects the resultant of EE and progestogens, and shows a positive association with nAPCsr and 
relative risks of venous thrombosis reported in the literature. 
Contraceptive N TBG (nmol/L) TSH (mIU/L) 
Mean MD 95% CI Mean MD 95% CI 
Cu-IUD 17 366 Ref 2.13 Ref 
LNG-IUD 60 331 −35 −71 to 0 2.24 0.12 −0.66 to 0.89 
150mcg LNG/30mcg EE 71 487 121 79 to 162 2.72 0.59 −0.19 to 1.38 
150mcg DSG/30mcg EE 16 629 263 199 to 327 2.91 0.78 −0.46 to 2.02 
3 mgDRSP/30mcg EE 46 582 216 160 to 272 3.01 0.89 −0.25 to 2.02 
2 mg CPA/35mcg EE 21 605 238 180 to 297 2.71 0.58 −0.64 to 1.81 
FT4 (pmol/L) Risk Ranking
Mean MD 95% CI OR 95%CI Reference
13.52 Ref 1.0
14.77 1.25 0.22 to 2.29 0.3 0.1 to 1.1 [15]
14.97 1.45 0.53 to 2.38 3.6 2.9 to 4.6 [2]
14.42 0.90 −0.15 to 1.96 7.3 5.3 to 10.0 [2]
14.23 0.72 −0.27 to 1.70 6.3 2.9 to 13.7 [2]
13.75 0.24 −0.74 to 1.21 6.8 4.6 to 10.0 [2]
Table 2. Means and 95% CI of TBG, TSH and FT4, and their risk ranking according to the literature.
TBG, thyroxine binding globulin; TSH, thyroid stimulating hormone; FT4, free thyroxine; MD, mean dif-
ference; CI, confidence interval; OR, odds ratio; IUD, intrauterine device; LNG, levonorgestrel; Cu, copper; 
EE, ethinylestradiol; DSG, desogestrel; DRSP, drospirenone; CPA, cyproterone acetate.
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Contraceptive N TBG (nmol/L) TSH (mIU/L) 
Mean MD 95% CI Mean MD 95% CI 
Cu-IUD 17 366 Ref 2.13 Ref 
LNG-IUD 60 331 −35 −71 to 0 2.24 0.12 −0.66 to 0.89 
150mcg LNG/30mcg EE 71 487 121 79 to 162 2.72 0.59 −0.19 to 1.38 
150mcg DSG/30mcg EE 16 629 263 199 to 327 2.91 0.78 −0.46 to 2.02 
3 mgDRSP/30mcg EE 46 582 216 160 to 272 3.01 0.89 −0.25 to 2.02 
2 mg CPA/35mcg EE 21 605 238 180 to 297 2.71 0.58 −0.64 to 1.81 
FT4 (pmol/L) Risk Ranking
Mean MD 95% CI OR 95%CI Reference
13.52 Ref 1.0
14.77 1.25 0.22 to 2.29 0.3 0.1 to 1.1 [15]
14.97 1.45 0.53 to 2.38 3.6 2.9 to 4.6 [2]
14.42 0.90 −0.15 to 1.96 7.3 5.3 to 10.0 [2]
14.23 0.72 −0.27 to 1.70 6.3 2.9 to 13.7 [2]














Figure 1. The association between TBG and nAPCsr.  Equation: log10(TBG) = 2.494 + (nAPCsr * 0.068). 
Pearson’s correlation coeffi cient is 0.714 (p<0.001).
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General discussion and summary
Since the introduction of the first oral contraceptive pill in 1959, the development of contracep-
tives with new compounds and routes of administration was focused on reducing side effects, 
while maintaining the benefits. This thesis focuses on venous thrombosis as a rare, but serious 
side effect of hormonal contraceptive use. Nowadays it is known that use of different hormonal 
contraceptives is associated with different thrombotic risks, dependent on the estrogen dose and 
progestogen type of the hormonal contraceptive.
The first objective of this thesis was to investigate effectiveness, bleeding-pattern, minor side 
effects and acceptability during use of quadriphasic oral contraceptives compared with mono-
phasic oral contraceptives (chapter 2). The second objective was to evaluate the levels of free 
TFPI and free Protein S as the main determinants of the thrombin generation-based APC resis-
tance test, during use of different hormonal contraceptives (chapter 3). The third objective was to 
evaluate whether SHBG acts as a marker for venous thrombosis during use of different hormonal 
contraceptives, and to assess if SHBG reflects the ethinylestradiol levels of hormonal contracep-
tives (chapter 4, 5). The fourth objective was to investigate the thrombotic risk of a new combined 
oral contraceptive containing dienogest and estradiol valerate administered in a quadriphasic 
schedule (chapter 6). The last objective was to assess the association between the levels of TBG, 
FT4 and TSH during use of different hormonal contraceptives and their risk of venous thrombosis 
(chapter 7).
Hormonal contraceptives and venous thrombosis
New formulas and schedules of administration
In chapter 2 we systematically reviewed the literature for randomized controlled trials comparing 
monophasic oral contraceptives with quadriphasic oral contraceptives, and planned to perform 
a meta-analysis for the outcomes on contraceptive effectiveness, bleeding pattern, minor side 
effects and acceptability. One double-blind, double-dummy randomized controlled trial comparing 
a quadriphasic oral contraceptive containing dienogest and estradiol valerate with a monophasic 
oral contraceptive containing 100 µg levonorgestrel and 20 µg ethinylestradiol was included. 
Contraceptive effectiveness, intracyclic bleeding and discontinuation due to side effects were 
similar for quadriphasic and monophasic pills. The number of women experiencing amenorrhea 
was higher in the quadriphasic group than in the monophasic group. Users of quadriphasic pills 
reported fewer bleeding and spotting days and fewer bleeding and spotting episodes than users 
of monophasic pills but it was unclear whether this was scheduled by the user or unscheduled. 
More women using quadriphasic oral contraceptives reported breast pain than women using 
monophasic oral contraceptives.
We concluded that the available evidence is insufficient to determine whether quadriphasic oral 
contraceptives differ from monophasic oral contraceptives in contraceptive effectiveness, bleed-
ing pattern, minor side effects and acceptability, since only one randomized controlled trial could 
be included. Studies that compare quadriphasic and monophasic oral contraceptives with an 
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identical progestogen and estrogen type are needed to determine whether the quadriphasic 
approach differs from the monophasic approach. Studies that compare quadriphasic pills with 
monophasic pills containing 30µg ethinylestradiol are indicated to determine whether quadri-
phasic oral contraceptives have an advantage over the current, first choice oral contraceptive. 
In the absence of proven advantages of multiphasic oral contraceptives, and because of the 
greater complexity of the multiphasic approach and the higher costs of multiphasic oral contra-
ceptives, we recommend monophasic pills as first choice for women starting oral contraceptive 
use. Monophasic pills containing 30 µg estrogen are preferred over 20 µg estrogen since the 
latter causes more bleeding problems and more often lead to discontinuation of use than those 
containing 30 µg (5).
Biological explanation
TFPI and Protein S
In chapter 3 we assessed the effect of hormonal and non-hormonal contraceptives with different 
routes of administration on free TFPI and free Protein S levels, as determinants of the thrombin 
generation-based APC resistance test. In addition, we measured APC sensitivity ratios (nAPCsr) by 
using the thrombin generation-based APC resistance test. We observed that users of contracep-
tives with the highest risk of venous thrombosis had the lowest free TFPI and free Protein S levels, 
and vice versa, women who used contraceptives with the lowest risk of venous thrombosis had 
the highest free TFPI and free Protein S levels. Furthermore, a negative association was observed 
between levels of free TFPI and APC resistance, and between free Protein S and APC resistance. 
Our study confirms that the different thrombotic risks associated with use of different hormonal 
contraceptives are reflected in the levels of free TFPI and free Protein S. Besides, our results 
confirm the hypothesis that the differences in APC resistance induced by hormonal contraceptives 
can at least be partially explained by different effects on free TFPI and free Protein S levels.
The lower free TFPI and free Protein S levels during use of third generation combined oral con-
traceptives or combined oral contraceptives containing cyproterone acetate or drospirenone are 
in concordance with several other studies on the effect of combined oral contraceptives on levels 
of free TFPI and free Protein S (6-11). Unfortunately, in our study the sample sizes of the groups of 
users of the vaginal ring and users of the transdermal patch were too small to draw conclusions. 
Since use of the transdermal patch and vaginal ring is associated with an increased risk of venous 
thrombosis with ORs of 7.9 and 6.5 respectively compared with non-use (12), decreased levels of 
both free TFPI and free Protein S are expected. Two studies have been performed on the levels 
of protein S in users of the transdermal patch or vaginal ring and the results were conflicting 
(13;14). A study with an adequate sample size is indicated to investigate the free Protein S and 
TFPI levels during use of the transdermal patch and vaginal ring. 
The mechanism for the decrease in free Protein S and free TFPI has been studied, but not yet 
fully unraveled. Kemmeren et al. explained the differences in free Protein S induced by various 
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oral contraceptives by the interaction between Protein S and C4BP. C4BP binds Protein S in a 
high-affinity complex (7). They observed that total Protein S was decreased by third generation 
combined oral contraceptives containing desogestrel but was hardly affected by second genera-
tion combined oral contraceptives containing levonorgestrel and that both oral contraceptives 
equally lowered C4BP. As a result, free Protein S levels increased in users of the combined oral 
contraceptive with levonorgestrel and decreased in users of the combined oral contraceptive 
with desogestrel. Free Protein S forms a complex with free TFPI and acts as cofactor of TFPI 
through the extrinsic pathway (15-19). A possible explanation of the concomitant decrease in free 
TFPI levels could be that binding of free TFPI to free Protein S protects free TFPI from proteolytic 
degradation or slows down the clearance of free TFPI. A decrease of free Protein S will therefore 
be accompanied by a decrease in free TFPI. Further, since free Protein S and free TFPI are both 
produced by the endothelium it is likely that TFPI production or release is also influenced by hor-
monal contraceptives; both proteins share the endothelium as common production site. In addi-
tion, the secretion of TFPI from endothelial cells might be coupled to Protein S secretion, as has 
recently been discovered for Protein S and the beta-chain of C4BP by Carlsson et al. (18;20). Future 
studies are indicated to unravel the mechanism of the decreased free TFPI and free Protein S 
levels during use of hormonal contraceptives and the association of their relationship with the 
risk of venous thrombosis.
Predicting thrombotic risk by use of surrogate markers
In chapter 4 we focused on SHBG as potential marker for venous thrombosis during use of hor-
monal contraceptives. We investigated whether a positive association could be found between 
levels of SHBG and APC resistance and between levels of SHBG and relative risks of venous throm-
bosis as reported in the literature during use of different combined oral contraceptives, LNG-IUD 
and copper-IUD, transdermal patch and vaginal ring. APC resistance was determined using the 
thrombin generation-based APC resistance test. The study demonstrates that users of contracep-
tives with a higher risk of venous thrombosis, i.e. third generation combined oral contraceptives, 
oral contraceptives containing cyproterone acetate or drospirenone, the transdermal patch and 
vaginal ring had higher SHBG levels than users of a second generation levonorgestrel combined 
oral contraceptive, which carry a lower thrombotic risk. The lowest SHBG levels were found during 
use of the LNG-IUD, which is not associated with an increased risk of venous thrombosis. A posi-
tive association was found between SHBG levels and APC resistance and between SHBG levels 
and the relative risks as reported in the literature. These results suggest that SHBG is a useful 
marker to estimate the risk of venous thrombosis during use of hormonal contraceptives. We rec-
ommend that the effect of a new hormonal contraceptive on SHBG should be measured before 
licensing, and compared with the effect on the combined oral contraceptive with the lowest risk 
of venous thrombosis, i.e. containing 30 µg ethinylestradiol and 150 µg levonorgestrel. 
In chapter 5 we determined the effect of the ethinylestradiol dose of combined oral contracep-
tives on SHBG levels, since the estrogen dose is thought to be the most important factor in 
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hormonal contraceptives in causing the increased risk of venous thrombosis. In this study we 
observed that women using a combined oral contraceptive with ≥ 35 µg ethinylestradiol had 
higher SHBG levels than women using a combined oral contraceptive with 20 µg ethinylestradiol. 
However, SHBG levels were only slightly higher in users of a combined oral contraceptive with 30 
µg ethinylestradiol than 20 µg ethinylestradiol.
Our results of SHBG during use of combined oral contraceptives, the transdermal patch and the 
vaginal ring are in concordance with other studies on the effect of hormonal contraceptives on 
levels of SHBG (3;21-26). We are not aware of studies published about SHBG during use of the 
LNG-IUD, or studies about the effect of different ethinylestradiol levels on SHBG. 
Stegeman et al. (27) investigated whether increased SHBG levels are causally related to venous 
thrombosis in women not using hormonal contraceptives. They used a Mendelian randomization 
approach and showed that SHBG is only a marker for venous thrombosis during hormonal contra-
ceptive use, and not a cause for an increased risk of venous thrombosis per se. 
Some researchers have questioned whether SHBG can act as a marker for venous thrombosis. They 
stated that SHBG has no relation with coagulation, is not validated as a marker and affected by 
many factors not involved by coagulation (28). Currently, a biological explanation for the associa-
tion between the changes in SHBG levels and APC resistance induced by hormonal contraceptives 
indeed is lacking. Our study supports the hypothesis of Odlind et al. (21) that SHBG reflects the 
overall estrogenicity of a hormonal contraceptive, and thereby the risk of venous thrombosis. SHBG 
and several coagulation factors and anticoagulant proteins are synthesized in the liver, and hor-
monal contraceptives, which are metabolized in the liver, might interfere with the synthesis of both 
SHBG and coagulation factors. Further research is needed to understand the association between 
increased SHBG levels and the increased risk of venous thrombosis during use of hormonal contra-
ceptives, which, however, is not a prerequisite for its use as a marker of thrombogenicity. 
We acknowledge that clinical data on the risk of venous thrombosis of new hormonal contracep-
tives are in theory to be preferred over markers such as SHBG. However, a non-clinical marker 
has the advantage that fewer women need to suffer venous thrombosis before a decision can be 
made. In addition, a marker should be validated in a prospective trial in which both the marker 
and the clinical endpoint are assessed (28). Given the low incidence of venous thrombosis during 
oral contraceptive use, a high number of participants is necessary in clinical studies to provide 
absolute and relative risks, which would be almost impossible before market authorization (29). 
Hence, during the developmental phase of a new contraceptive, the thrombotic risk can be esti-
mated by using SHBG as marker and by comparing the SHBG levels of the new contraceptive 
with the combined oral contraceptive with the lowest risk of venous thrombosis, i.e. contain-
ing levonorgestrel. Thrombin generation-based APC resistance is a validated marker for venous 
thrombosis (8), but a complex measurement which cannot be performed in every laboratory. SHBG, 
however, can easily be measured in every routine laboratory. The EMA therefore now recommends 
SHBG measurement in guidelines applying to the clinical development of a new combined hor-
monal contraceptive (30). 
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In chapter 6 we investigated the thrombogenicity of a new oral contraceptive containing dienogest 
and estradiol valerate administered in a quadriphasic schedule. APC resistance and SHBG levels 
were measured in participants using this new oral contraceptive and compared with APC resis-
tance and SHBG levels during use of a monophasic oral contraceptive containing levonorgestrel 
and ethinylestradiol. We observed no clear differences in APC resistance and SHBG as markers for 
venous thrombosis between the oral contraceptives. During the pill cycle, SHBG levels increased 
gradually in both dienogest with estradiol valerate users as well as in and in levonorgestrel with 
ethinylestradiol users. No differences in APC resistance were observed during the pill cycle.
These results are in concordance with two studies sponsored by the manufacturer. Klipping et 
al. (1) conducted a randomized, open label, cross-over study of dienogest with estradiol valer-
ate and monophasic levonorgestrel with ethinylestradiol and observed lower nAPCsr and lower 
SHBG levels in users of dienogest with estradiol valerate than in users of levonorgestrel with 
ethinylestradiol. Junge et al. (2) performed a randomized, open label study and also observed less 
pronounced SHBG levels in users of dienogest with estradiol valerate than in users of triphasic 
levonorgestrel withethinylestradiol. In our study, nAPCsr levels were overall lower in users of 
dienogest with estradiol valerate, but the differences were not pronounced and not statistically 
significant. This can be due to a smaller sample sizes in the studies of the manufacturer. Based on 
the results of these three studies, it can be stated, however, that dienogest with estradiol valerate 
does not lead to a more thrombogenic state than levonorgestrel with ethinylestradiol. However, 
clinical studies assessing the absolute and relative risk of thrombosis in women using dienogest 
with estradiol valerate are indicated to confirm this.
Dienogest has, in addition to estradiol valerate, also been combined with ethinylestradiol in a 
combined oral contraceptive pill (Valette®, Bayer Schering Pharma, Berlin, Germany; not avail-
able in the Netherlands). In a study by Wiegratz et al. (3) users of oral contraceptives containing 
2mg dienogest and 20 µg ethinylestradiol had higher SHBG levels than users of oral contracep-
tives containing 100 µg levonorgestrel and 20 µg ethinylestradiol. This indicates that dienogest 
is a less anti-estrogenic progestogen than levonorgestrel. In our study no differences in SHBG 
were observed between users of dienogest with estradiol valerate and levonorgestrel with ethi-
nylestradiol. No studies have been published yet on the effect of dienogest with ethinylestradiol 
on nAPCsr, or the risk of venous thrombosis of combined oral contraceptives containing estradiol 
valerate as estrogen content. Estradiol valerate seems to have a favorable effect on the risk 
of venous thrombosis, but has not been combined with other progestogens before. Therefore, 
the impact of estradiol valerate alone on venous thrombosis remains unknown. Future research 
should focus on the effect of estradiol valerate as the estrogen compound of a combined oral 
contraceptive on the risk of venous thrombosis compared with ethinylestradiol.
In 2011, a new monophasic combined oral contraceptive composed of the progestogen nomege-
strol acetate and the estrogen 17ß-estradiol (Zoely®, Merck & Co., Inc., Whitehouse Station, New 
Jersey USA) was marketed. Gaussem et al. (4) compared APC resistance and SHBG levels during 
use of this new combined oral contraceptive with the monophasic combined oral contraceptive 
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containing 100 µg levonorgestrel and 20 µg ethinylestradiol. SHBG levels were similar for the 
two oral contraceptives, and APC resistance levels were more favorable during use of nomege-
strol acetate with estradiol than during use of levonorgestrel with ethinylestradiol. Gaussem et al. 
observed no increase in markers for the risk of venous thrombosis during use of the new combined 
oral contraceptive containing nomegestrol actetate with estradiol compared with levonorgestrel 
with ethinylestradiol. Clinical data of independent studies are indicated to assess the absolute 
and relative risk of venous thrombosis during use of this new combined oral contraceptive. 
Thyroid parameters and venous thrombosis
In chapter 7 we investigated whether there is an association between the levels of thyroid param-
eters during use of hormonal contraceptives and the risk of venous thrombosis. We measured 
the thyroid parameters TBG, FT4 and TSH, as well as APC resistance determined by the thrombin 
generation-based APC resistance test. We observed that users of different hormonal contracep-
tives had different levels of TBG, TSH and FT4. A positive association was found between TBG 
levels and nAPCsr. Users of hormonal contraceptives associated with an increased risk of venous 
thrombosis had higher TBG levels than users of the LNG-IUD, which is not associated with an 
increased risk of venous thrombosis. TSH levels showed the same, but less pronounced, trend 
during hormonal contraceptive use: users of hormonal contraceptives with a high risk of venous 
thrombosis had higher TSH levels than users of low-risk hormonal contraceptives. FT4 levels 
stayed within the normal range, indicating that use of hormonal contraceptives does not lead to 
a hyperthyroid state. Therefore, the increased risk of venous thrombosis during use of hormonal 
contraceptives cannot be explained by hypercoagulability caused by a hyperthyroid state as a 
result of hormonal contraceptive use. 
The increased levels of TBG in users of combined oral contraceptives are in concordance with 
other studies (3;22;31-34). We found a less pronounced increase in TSH levels and hardly any 
changes in FT4 levels, as was also observed by Ågren et al. and Sänger et al. (32;33). 
Currently, a biological explanation of the increased risk of venous thrombosis during use of com-
bined hormonal contraceptives is lacking. It seems likely that the liver plays a modulating role 
in the increased risk of venous thrombosis during use of combined hormonal contraceptives: the 
serum levels of hepatic binding globulins such as TBG and SHBG are increased during use of 
combined hormonal contraceptives, coagulation factors are produced in the liver and hormonal 
contraceptives are metabolized in the liver. Possibly, combined hormonal contraceptives interfere 
with the synthesis of both binding globulins and coagulation factors. Estrogens regulate levels of 
polymorphic glycoproteins, e.g. hepatic binding globulins, by affecting their sialylation (35). Sialic 
acid occupies the terminal ends of oligosaccharides of glycoproteins and prevents degradation 
of these molecules. A high sialic acid content leads to slower breakdown and higher circulating 
serum levels of glycoproteins (36). Besides binding globulins such as TBG and SHBG, coagulation 
factors (e.g. FV) and anticoagulation factors (e.g. APC) are all glycoproteins and therefore contain 
sialic acid. Hau et al. observed that desialylated APC was more active than normal APC, suggesting 
121
General discussion and summary
that sialic acid inhibits the activity of APC (37). Fernández et al. studied the protective role of the 
sialic acid content of FV in its inactivation by APC and found that desialylation of FV increases 
its susceptibility for proteolytic inactivation by APC (38). Therefore, in the case of increased sialic 
acid, it is possible that FV becomes more resistant for the action of APC which increase the throm-
botic risk. We hypothesize that the increased sialic acid compound of glycoproteins, as a result of 
estrogen administration during use of hormonal contraceptives, contributes to the increased risk 
of venous thrombosis associated with hormonal contraceptive use. Further research is indicated 
to assess the effect of different hormonal contraceptives on the sialic acid content of glycopro-





The combined oral contraceptive with 30 µg ethinylestradiol and 150 µg levonorgestrel is • 
recommended over other combined hormonal contraceptives.
The new oral contraceptive containing dienogest with estradiol valerate has a similar throm-• 
botic profile as levonorgestrel with ethinylestradiol.
A quadriphasic regimen is not favorable compared with monophasic preparations regarding • 
effectiveness, side effects and acceptability.
Use of hormonal contraceptives does not lead to a subclinical hyperthyroid state.• 
Research
Clinical epidemiological studies are necessary to assess the absolute and relative risk of the • 
quadriphasic oral contraceptive containing dienogest with estradiol valerate, and to confirm 
the hypothesis that this quadriphasic oral contraceptive has a similar risk of venous throm-
bosis as the monophasic oral contraceptive containing levonorgestrel with ethinylestradiol.
Independent laboratory studies are indicated to estimate the thrombotic risk of the new • 
monophasic oral contraceptive containing nomegestrol acetate with estradiol by measuring 
nAPCsr and SHBG levels. Clinical epidemiologic studies are indicated to assess the absolute 
and relative risk of venous thrombosis during use of this new oral contraceptive.
Future studies examining the mechanism of the reduction of free PS and free TFPI during use • 
of hormonal contraceptives are indicated to gain more insight in the basis of the increased 
risk of venous thrombosis.
Before a new hormonal contraceptive is licensed or used in practice, the effect of the prepara-• 
tion on nAPCsr and SHBG levels should be evaluated to estimate the risk of venous thrombo-
sis. These measurements should be included in the general benefit-risk analysis of the new 
preparation. The new prescription should be compared with an oral contraceptive containing 
30 µg ethinylestradiol and 150 µg levonorgestrel.
Laboratory studies are indicated to assess the biological explanation for the association • 
between the changes in SHBG levels and nAPCsr induced by hormonal contraceptives.
Sialic acid should be measured in users of different hormonal contraceptives to investigate • 
the role of sialic acid and its influence on glycoproteins in the etiology of venous thrombosis 
during use of hormonal contraceptives.
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Kort na de introductie van de combinatie anticonceptiepil in 1959 werd de eerste casus van 
veneuze trombose tijdens gebruik van een anticonceptiepil beschreven. Veneuze trombose is 
een zeldzame aandoening bij vrouwen in de fertiele levensfase en heeft een incidentie van 
ongeveer 3 per 10.000 vrouwen per jaar. Het gebruik van orale combinatie anticonceptie is geas-
socieerd met een verhoogd risico op veneuze trombose: twee tot zes keer zo hoog ten opzichte 
van gezonde vrouwen die geen orale anticonceptie gebruiken. Ondanks de lage incidentie is het 
gebruik van hormonale anticonceptie toch een veelvoorkomende oorzaak van veneuze trombose, 
omdat wereldwijd miljoenen vrouwen een anticonceptiepil gebruiken. 
De doelstelling van dit proefschrift was om het risico op veneuze trombose tijdens gebruik van 
verschillende hormonale anticonceptiva te bestuderen en te vergelijken, en meer inzicht te 
krijgen in het mechanisme dat ten grondslag ligt aan het verhoogde risico op veneuze trombose 
tijdens gebruik van hormonale anticonceptie. 
Hormonale anticonceptie en veneuze trombose
Sinds de introductie van de combinatie anticonceptiepil werden nieuwe hormonale anticoncep-
tiva ontwikkeld met als doel om bijwerkingen (zoals veneuze trombose) te verminderen, en tegeli-
jkertijd de voordelen (zoals het voorkómen van zwangerschap en cyclusregulatie) te behouden. 
De verschillende methoden van aanpak om de risico’s te verlagen zijn onder te verdelen in vier 
categorieën:
Het verlagen van de dosis steroïden
Aanvankelijk werd geprobeerd het risico op veneuze trombose te verlagen door de dosis ste-
roïden te verlagen, wat vooral bij het aanpassen van de dosis oestrogeen effectief bleek te zijn. 
Dit verband was recht evenredig: hoe lager de dosis ethinylestradiol (het meest gebruikte synthe-
tische oestrogeen in hormonale anticonceptiva), des te lager was het risico op veneuze trombose. 
Tegenwoordig bevatten de meest voorgeschreven combinatie anticonceptiepillen 20 of 30ug 
ethinylestradiol. 
Nieuwe toedieningschema’s
Vervolgens werden er nieuwe toedieningschema’s ontwikkeld, zoals de tweefasen of driefasen 
anticonceptiepillen. Studies hebben aangetoond dat  deze toedieningschema’s echter geen ver-
laging gaven van het risico op veneuze trombose. Daarnaast werd in meta-analyses onvoldoende 
bewijs gevonden voor een groter gebruiksgemak of een vermindering van andere bijwerkingen 
(bijvoorbeeld tussentijds bloedverlies) tijdens gebruik van een twee- of driefasen preparaat. 
Recent werd een nieuwe pil op de markt gebracht met een vierfasen toedieningschema. Het bevat 
een nieuw oestrogeen, estradiolvaleraat, en een progestageen dat nog niet eerder in Nederland 
werd gebruikt, dienogest. In Hoofdstuk 2 worden de resultaten beschreven van een systematische 
review van gerandomiseerde studies waarin vierfasen orale anticonceptiva worden vergeleken 
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met eenfase orale anticonceptiva. Het doel was om het vierfasen toedieningschema van orale 
anticonceptiva te vergelijken met het eenfase schema op de uitkomsten van effectiviteit, bloed-
ingpatroon en de mate waarin vrouwen het anticonceptivum verdragen. 
Er was één studie die aan de inclusiecriteria voldeed, waarin een vierfasen anticonceptiepil 
met dienogest en estradiolvaleraat werd vergeleken met een eenfase anticonceptiepil met 100 
µg levonorgestrel en 20 µg ethinylestradiol. In deze studie werden geen verschillen gevonden 
tussen het vierfasen preparaat en het eenfase preparaat met betrekking tot de effectiviteit en de 
mate waarin vrouwen het anticonceptivum verdragen. Er werd tijdens gebruik van de vierfasen 
pil vergeleken met de eenfase pil vaker een kortere duur van de onttrekkingbloeding of een 
amenorroe geconstateerd.
De conclusie was dat de literatuur onvoldoende wetenschappelijk bewijs levert om vierfasen en 
eenfase toedieningschema’s gedegen met elkaar te vergelijken en om vast te stellen of er ver-
schillen zijn tussen deze toedieningschema’s, aangezien er slechts één studie geïncludeerd kon 
worden. De klassieke eenfase anticonceptiepil wordt nog steeds geadviseerd als eerste keuze 
voor vrouwen die starten met het gebruik van de combinatie anticonceptiepil.
Nieuwe steroïden
In de afgelopen jaren zijn diverse pillen met verschillende nieuwe typen steroïden op de markt 
gebracht. Deze voldeden echter niet altijd aan het gewenste doel van vermindering van bijwerkin-
gen. Epidemiologische studies uit de jaren negentig toonden aan dat orale anticonceptiva met 
de derde generatie progestagenen gestodeen of desogestrel, welke werden ontwikkeld om de 
arteriële bijwerkingen van de pil te doen verminderen, een verdubbeling gaven van het risico op 
veneuze trombose ten opzichte van tweede generatie orale anticonceptiva met levonorgestrel. 
Later bleek dat ook orale anticonceptiva met cyproteronacetaat of drospirenon als progestagene 
component een verdubbeling gaven van het risico op veneuze trombose ten opzichte van de 
anticonceptiepillen met levonorgestrel. 
Nieuwe toedieningroutes
Naast veranderingen in dosis, type steroïden en meerfasen toedieningschema’s, werden ook 
nieuwe toedieningsroutes ontwikkeld in de vorm van het hormoonhoudende (levonorgestrel 
bevattende) spiraaltje, de vaginale ring en de anticonceptie pleister. Recent werd bekend dat het 
hormoonhoudend spiraaltje geen verhoogd risico geeft op veneuze trombose terwijl de vaginale 
ring en de anticonceptie pleister net als derde generatiepillen bijna een verdubbeling geven van 
het risico op veneuze trombose ten opzichte van de tweede generatiepil met levonorgestrel.
Biologische verklaring 
Het exacte biologische mechanisme van het verhoogde risico op veneuze trombose tijdens 
gebruik van hormonale anticonceptie is onbekend. Diverse laboratoriumstudies toonden aan dat 
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de concentraties van stollingsfactoren beïnvloed worden door het gebruik van hormonale anti-
conceptie, maar de resultaten van de verschillende onderzoeken zijn niet eenduidig.
Een doorbraak was de ontdekking dat het verhoogde tromboserisico deels verklaard kan worden 
door de effecten van hormonale anticonceptie op geactiveerd proteïne C (APC), een eiwit dat de 
stollingscascade remt. Gebruik van hormonale anticonceptie leidt in wisselende mate tot resist-
entie voor de werking van APC, waardoor de noodzakelijke remming van de stollingscascade 
verminderd wordt. Dit leidt tot een verhoogde kans op het ontwikkelen van veneuze trombose. De 
mate van APC resistentie kan gemeten worden met de thrombin generation-based APC resistance 
test, welke een betrouwbare marker bleek te zijn voor het risico op veneuze trombose. 
Tissue Factor Pathway Inhibitor (TFPI) en Proteïne S zijn net als APC fysiologische remmers van 
de stollingscascade. Naast hun individuele remming van de stolling zijn zij ook van invloed op de 
werking van APC, en zijn het belangrijke determinanten van de thrombin generation-based APC 
resistance test. Recent bleken de levels van TFPI en Proteïne S ook beïnvloed te worden door het 
gebruik van hormonale anticonceptiva, wat mogelijk bijdraagt aan de hogere stollingsneiging 
tijdens gebruik van deze anticonceptiva. 
In Hoofdstuk 3 worden de resultaten van een dwarsdoorsnede onderzoek beschreven waarin de 
effecten van gebruik van verschillende hormonale anticonceptiva op de concentraties van vrij 
TFPI en vrij Proteïne S (de werkzame fracties) worden onderzocht. Het doel van deze studie was 
om na te gaan of de verschillen in tromboserisico bij gebruik van verschillende hormonale anti-
conceptiva weerspiegeld werden in de concentraties van vrij TFPI en vrij Proteïne S in het bloed. 
Daarnaast werd de mate van APC resistentie gemeten met behulp van de thrombin generation-
based APC resistance test.
Gebruiksters van hormonale anticonceptiva met het hoogste tromboserisico (orale anticonceptiva 
met desogestrel, cyproteronacetaat of drospirenon) hadden de laagste vrij TFPI en vrij Proteïne S 
concentraties. Verder hadden gebruiksters van het hormoonhoudend spiraaltje, waarvan bekend 
is dat het geen verhoging geeft van het risico op veneuze trombose, de hoogste vrij TFPI en vrij 
Proteïne S concentraties in het bloed. Lage vrij TFPI en vrij Proteïne S waarden waren geasso-
cieerd met een verhoogde APC resistentie wat een risicofactor is voor veneuze trombose.
Helaas waren de groepen met gebruiksters van de vaginale ring en de anticonceptiepleister te 
klein voor een betrouwbare analyse.
De uitkomsten van deze studie laten zien dat de verschillen in risico op veneuze trombose die 
gepaard gaan met het gebruik van verschillende hormonale anticonceptiva weerspiegeld worden 
in de concentraties van vrij TFPI en vrij Proteïne S. Daarmee ondersteunen ze de hypothese dat 
de verschillen in APC resistentie veroorzaakt door gebruik van verschillende hormonale anticon-
ceptiva ten minste gedeeltelijk verklaard kunnen worden door de effecten op vrij TFPI en vrij 
Proteïne S.
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Het voorspellen van tromboserisico met markers
Zodra een nieuw hormonaal anticonceptivum op de markt komt, is het belangrijk een indicatie te 
hebben van het tromboserisico zodat gebruiksters niet onnodig aan een hoog risico op veneuze 
trombose worden blootgesteld. Omdat veneuze trombose bij vrouwen in de fertiele levensfase 
een lage incidentie heeft is een zeer groot aantal gebruiksters nodig om het risico op veneuze 
trombose tijdens gebruik van een nieuw hormonaal anticonceptivum vast te stellen (circa 500 
000). Dit is nagenoeg onmogelijk om uit te voeren voordat een nieuw preparaat op de markt komt. 
Om toch een schatting te kunnen maken van het tromboserisico kan gebruik worden gemaakt 
van markers. Zoals eerder vermeld, bleek APC resistentie gemeten met de thrombin generation-
based APC resistance test een gevalideerde marker voor veneuze trombose te zijn. 
In 2002 werd een studie gepubliceerd waarbij het transporteiwit Sex Hormone-Binding Glob-
ulin (SHBG transporteert oestrogeen en testosteron in het bloed) wordt genoemd als marker 
voor “oestrogeniciteit” en daarmee als marker voor veneuze trombose. Oestrogeniciteit werd 
gedefinieerd als de som van de effecten van het oestrogeen en het progestageen (dosis- en 
typeafhankelijk), resulterend in een netto effect. In twee observationele studies werd een verband 
gevonden tussen APC resistentie en SHBG levels bij gebruiksters van verschillende hormonale 
anticonceptiva en non-users. Hiermee werd de hypothese dat SHBG als marker fungeert voor 
veneuze trombose tijdens gebruik van hormonale anticonceptie versterkt.
Hoofdstuk 4 beschrijft een dwarsdoorsnede onderzoek waarin bij gebruiksters van verschillende 
hormonale anticonceptiva SHBG levels en APC resistentie werden bepaald. Het doel van de studie 
was om te onderzoeken of SHBG een goede marker is voor veneuze trombose tijdens gebruik van 
hormonale anticonceptiva. 
Gebruiksters van hormonale anticonceptiva met een hoog tromboserisico (anticonceptiepillen 
met desogestrel, gestodeen, cyproteronacetaat of drospirenon, de anticonceptiepleister en de 
vaginale ring) hadden hogere SHBG spiegels ten opzichte van gebruiksters van laag risico orale 
anticonceptiva zoals anticonceptiepillen met levonorgestrel. Gebruiksters van het hormoonhou-
dend spiraaltje, dat geassocieerd is met het laagste tromboserisico, hadden ook de laagste SHBG 
spiegels. Hetzelfde verband werd gevonden tussen de hoogte van de SHBG waarden en de mate 
van APC resistentie: gebruiksters met hogere SHBG waarden hadden ook een hogere APC resist-
entie.
Hoofdstuk 5 beschrijft de resultaten van een dwarsdoorsnede onderzoek naar het effect van de 
ethinylestradiol dosis in gecombineerde orale anticonceptiva op de SHBG spiegels. Het doel was 
om na te gaan of ook enkel de ethinylestradiol dosis van invloed is op de SHBG spiegels, onaf-
hankelijk van het progestageen.
Gebruiksters van een gecombineerde anticonceptiepil met ≥ 35 µg ethinylestradiol hadden 
hogere SHBG spiegels dan gebruiksters van een gecombineerde anticonceptiepil met 20 µg ethi-
nylestradiol. Het verschil in SHBG spiegels tussen gebruiksters van 30 µg en 20 µg was echter 
maar klein. De resultaten toonden aan dat de dosis ethinylestradiol gereflecteerd wordt in de 
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SHBG spiegels van gebruiksters van gecombineerde orale anticonceptiva, onafhankelijk van de 
progestagene component van de anticonceptiepil. 
De uitkomsten van beide studies ondersteunen de hypothese dat SHBG een goede en bruikbare 
marker is voor het risico op veneuze trombose tijdens gebruik van hormonale anticonceptiva. Wij 
adviseren dan ook om de SHBG spiegels en de mate van APC resistentie van nieuwe hormonale 
anticonceptiva te vergelijken met de meest gebruikte anticonceptiepil met ethinylestradiol en 
levonorgestrel, voordat het nieuwe preparaat op de markt wordt gebracht.
In Hoofdstuk 6 staan de resultaten beschreven van een gerandomiseerde studie naar het trom-
boserisico van de nieuwe vierfase anticonceptiepil met estradiolvaleraat en dienogest. De SHBG 
spiegels en APC resistentie tijdens gebruik van deze nieuwe pil werden vergeleken met de eenfase 
pil met ethinylestradiol en levonorgestrel. Het doel van de studie was om het tromboserisico van 
de nieuwe pil te schatten.
Gebruiksters van de nieuwe vierfase pil met estradiolvaleraat en dienogest hadden geen hogere 
of lagere SHBG spiegels of APC resistentie dan gebruiksters van de eenfase pil met ethinylestra-
diol en levonorgestrel. Tijdens de pilcyclus werd een geleidelijke stijging van de SHBG spiegels 
bij alle gebuiksters gemeten. Een mogelijke verklaring hiervoor was dat SHBG een halfwaardetijd 
heeft van enkele dagen.
Hieruit werd geconcludeerd dat de vierfase pil met estradiolvaleraat en dienogest geen hoger 
tromboserisico heeft dan de onderzochte eenfase pil. In de toekomst zijn klinische studies nodig 
om deze hypothese te bevestigen.
Schildklierparameters en veneuze trombose
Naast gebruik van hormonale anticonceptie is hyperthyreoidie ook geassocieerd met een ver-
hoogd risico op veneuze trombose. Patienten met hyperthyreoidie hebben onder andere hogere 
levels vrij Thyroxine (T4), wat het stollingssysteem beïnvloedt. Gedacht wordt dat dit de oorzaak 
is van het verhoogde tromboserisico.  
Gebruik van hormonale anticonceptie leidt tot licht verhoogde waardes van de schildklierpa-
rameters. Of de verhoogde levels van deze schildklierparameters tijdens gebruik van hormonale 
anticonceptie geassocieerd zijn met het verhoogde tromboserisico tijdens gebruik van deze hor-
monale anticonceptie was nog niet onderzocht.
In Hoofdstuk 7 worden de resultaten besproken van een dwarsdoorsnede onderzoek waarbij 
in gebruiksters van verschillende hormonale anticonceptiva de spiegels van Thyroxine Binding 
Globulin (TBG), T4 en Thyroid Stimulating Hormone (TSH) als schildklierparameters, en APC 
resistentie als marker voor veneuze trombose werden bepaald. Het doel van de studie was om te 
onderzoeken of de verhoogde spiegels van deze schildklierparameters tijdens gebruik van hor-
monale anticonceptiva geassocieerd zijn met het verhoogde risico op veneuze trombose tijdens 
gebruik van deze hormonale anticonceptiva. 
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Gebruiksters van de onderzochte hormonale anticonceptiva hadden verschillende spiegels van 
TBG, TSH en vrij T4. Er werd een verband gevonden tussen de TBG spiegels en de APC resistentie 
en tussen TBG spiegels en het risico op veneuze trombose. Gebruik van het hormonaal anticon-
ceptivum met het hoogste risico op veneuze trombose (in deze studie de orale anticonceptiepil 
met cyproteronacetaat of drospirenon) gaf de hoogste TBG spiegels en de hoogste APC resisten-
tie. Gebruiksters van het hormoonhoudende spiraaltje, wat niet geassocieerd is met een verhoogd 
tromboserisico, hadden de laagste TBG spiegels en de laagste APC resistentie. De vrij T4 spiegels 
bleven binnen de normaalwaarden bij alle gebruiksters.
De uitkomsten van deze studie toonden geen verband aan tussen het verhoogde risico op veneuze 
trombose bij het gebruik van hormonale anticonceptiva en de verhoogde stollingsneiging als 
gevolg van hyperthyreoidie bij het gebruik van deze hormonale anticonceptiva.
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